"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 2625579 A,007-189-110-082-761,1953-01-13,1953,US 14326550 A,1950-02-09,US 14326550 A,1950-02-09,Spark plug elbow and barrel sealing grommet,,UNITED AIRCRAFT CORP,FRAZEE JOHN D,,https://lens.org/007-189-110-082-761,Granted Patent,no,7,6,1,1,0,H01T13/06;;H01T13/06,H01T13/06,,0,0,,,,EXPIRED
2,US,A1,US 2007/0194153 A1,033-836-463-361-986,2007-08-23,2007,US 78398407 A,2007-04-13,US 78398407 A;;US 73128003 A;;US 43310202 P;;US 45474003 P,2002-12-13,Anti-clogging showerhead device,"A showerhead facilitating draining of water retained following shut-off. The showerhead includes a housing swivelably fitted on a ball-adapter which in turn includes an integral threaded segment for attachment to a water feed line. An air pathway is formed to extend from inside to outside the ball-adapter where it opens to generally atmospheric pressure. A flexible check valve in the form of an annular skirt is retained by an integral ring portion where the ball-adapter is threaded to the feed line. Under water-flow pressure, the skirt expands, blocking the passage. Upon shut-off, the skirt withdraws, instantly opening the air passage. Opening the showerhead to atmospheric pressure relieves the normally occurring suction effect which keeps water from draining completely from the showerhead spray holes. Thus avoiding the widespread problem of trapped water slowly evaporating and leaving behind stubborn and unsightly mineral deposits that eventually build up to clog showerhead spray holes.",FRAZEE JOHN S,FRAZEE JOHN S,,https://lens.org/033-836-463-361-986,Patent Application,yes,25,12,2,2,0,B05B1/18;;E03C1/08;;E03C2001/082;;E03C2201/70;;B05B15/50;;B05B15/654;;Y10T137/3294;;Y10T137/3294;;E03C1/08;;E03C2201/70;;B05B1/18;;E03C2001/082;;B05B15/654;;B05B15/50,B05B15/68;;E03C1/08,239/587.1;;239/428.5;;239/587.4,0,0,,,,EXPIRED
3,US,A,US 5794629 A,012-422-063-354-208,1998-08-18,1998,US 75730396 A,1996-11-27,US 75730396 A,1996-11-27,Method for treating ischemic brain stroke,"A method for treating a patient sustaining an acute ischemic stroke in the brain. The brain has a blood circulatory system including a torcular Herophili and first and second transverse venous sinuses adjoining the torcular Herophili. The method comprises at least partially occluding the first and second transverse venous sinuses in first and second locations, respectively, adjacent to the torcular Herophili to partially obstruct venous blood drainage while permitting some antegrade venous blood flow from at least one of the transverse venous sinuses. A flow of the patient's arterial blood is introduced into at least one of the transverse venous sinuses to provide a substantially continuous retrograde blood flow into the venous side of the brain of the patient to overcome the lack of arterial blood flow for a period of time until the patient exhibits at least some resolution of ischemic brain symptoms.",UNIV CALIFORNIA,FRAZEE JOHN G,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1996-11-25),https://lens.org/012-422-063-354-208,Granted Patent,yes,5,106,3,3,0,A61M1/3621;;A61M1/369;;A61M2205/366;;A61M2210/0693;;A61M1/3613;;A61M1/3621;;A61M1/369;;A61M2210/0693;;A61M2205/366;;A61M1/3613,A61M1/36,128/898;;604/49,5,2,016-418-785-908-149;;016-418-785-908-149,2300996;;10.1161/01.str.21.1.87;;2300996;;10.1161/01.str.21.1.87,"Frazee et al. Ischemic Brain Rescue By Transvenous Perfusion in Baboons With Venous Sinus Occlusion, Stroke , vol. 21, No. 1, Jan. 1990.;;Kar et al. Reversal of cerebral ischemia by transvenous retroperfusion of arterial blood. Circulation 80(4 Suppl. 2): II405, 1989.;;Frazee et al. Ischemic brain rescue by transvenous perfusion in baboons with venous sinus occlusion. Stroke 21:87 93, 1990.;;Kardos. Neuroperfusion, Inc., Summary Federal Report on Cerebral Retroperfusion Device for Ischemic Stroke 1993.;;Alexander et al. Transvenous Retroperfusion in an experimental model of cerebral ischemia improves somatosensory evoked potentials and cerebral perfusion. Stroke 25(3):753, 1994.",EXPIRED
4,US,B1,US 6386202 B1,008-461-483-577-843,2002-05-14,2002,US 31850799 A,1999-05-25,US 31850799 A;;US 9721704 W;;US 75730396 A,1996-11-27,Method for treating ischemic brain stroke,"
    Method and apparatus for treating a patient sustaining an acute ischemic stroke in a brain having a blood circulatory system including a torcular Herophili and adjoining transverse venous sinuses, includes steps for partially occluding the sinuses to partially obstruct venous blood drainage while permitting some antegrade venous blood flow from at least one of the sinuses. A flow of the patient's arterial blood is introduced into at least one of the sinuses to produce a continuous retrograde blood flow on the venous side of the brain. In an associated method including a blood pump and occlusion catheters, a heat exchanger is used to lower the temperature of the retrograde blood flow in order to achieve hypothermic treatment of the brain. 
",UNIV CALIFORNIA,FRAZEE JOHN G,,https://lens.org/008-461-483-577-843,Granted Patent,yes,6,55,3,3,0,A61M1/3621;;A61M1/369;;A61M2205/366;;A61M2210/0693;;A61M1/3613;;A61M1/3621;;A61M1/369;;A61M2210/0693;;A61M2205/366;;A61M1/3613,A61M1/36,128/898;;604/27,0,0,,,,EXPIRED
5,US,B2,US 7427037 B2,198-386-167-332-441,2008-09-23,2008,US 78398407 A,2007-04-13,US 78398407 A;;US 73128003 A;;US 43310202 P;;US 45474003 P,2002-12-13,Anti-clogging showerhead device,"A showerhead facilitating draining of water retained following shut-off. The showerhead includes a housing swivelably fitted on a ball-adapter which in turn includes an integral threaded segment for attachment to a water feed line. An air pathway is formed to extend from inside to outside the ball-adapter where it opens to generally atmospheric pressure. A flexible check valve in the form of an annular skirt is retained by an integral ring portion where the ball-adapter is threaded to the feed line. Under water-flow pressure, the skirt expands, blocking the passage. Upon shut-off, the skirt withdraws, instantly opening the air passage. Opening the showerhead to atmospheric pressure relieves the normally occurring suction effect which keeps water from draining completely from the showerhead spray holes. Thus avoiding the widespread problem of trapped water slowly evaporating and leaving behind stubborn and unsightly mineral deposits that eventually build up to clog showerhead spray holes.",FRAZEE JOHN S,FRAZEE JOHN S,,https://lens.org/198-386-167-332-441,Granted Patent,yes,25,11,2,2,0,B05B1/18;;E03C1/08;;E03C2001/082;;E03C2201/70;;B05B15/50;;B05B15/654;;Y10T137/3294;;Y10T137/3294;;E03C1/08;;E03C2201/70;;B05B1/18;;E03C2001/082;;B05B15/654;;B05B15/50,B05B15/02;;B05B15/68;;E03C1/10;;F16K24/00;;F23D11/34;;F23D11/38;;F23D14/50,239/109;;239/104;;239/111;;239/597;;239/707;;137/217,0,0,,,,EXPIRED
6,WO,A1,WO 1998/023217 A1,186-741-815-501-02X,1998-06-04,1998,US 9721704 W,1997-11-26,US 75730396 A,1996-11-27,METHOD FOR TREATING ISCHEMIC BRAIN STROKE,"Method and apparatus for treating a patient sustaining an acute ischemic stroke in a brain having a blood circulatory system including a torcular Herophili (97) and adjoining transverse venous sinuses (96), includes steps for partially occluding the sinuses to partially obstruct venous blood drainage while permitting some antegrade venous blood flow from at least one of the sinuses. A flow of the patient's arterial blood is introduced into at least one of the sinuses to produce a continuous retrograde blood flow on the venous side of the brain.",UNIV CALIFORNIA;;FRAZEE JOHN G,FRAZEE JOHN G,,https://lens.org/186-741-815-501-02X,Patent Application,yes,2,16,3,3,0,A61M1/3621;;A61M1/369;;A61M2205/366;;A61M2210/0693;;A61M1/3613;;A61M1/3621;;A61M1/369;;A61M2210/0693;;A61M2205/366;;A61M1/3613,A61M1/36,,0,0,,,,PENDING
7,US,A,US 2516557 A,139-445-530-993-242,1950-07-25,1950,US 4717648 A,1948-09-01,US 4717648 A,1948-09-01,Convertible nursery seat,,FRAZEE JOHN D;;RUSSELL WILLIAM H,FRAZEE JOHN D;;RUSSELL WILLIAM H,,https://lens.org/139-445-530-993-242,Granted Patent,no,4,6,1,1,0,A47K13/06;;A47K13/06,A47D15/00,,0,0,,,,EXPIRED
8,US,A,US 5062848 A,026-771-146-025-534,1991-11-05,1991,US 68010791 A,1991-03-26,US 68010791 A;;US 48990090 A,1990-03-07,Hemostatic clip and applicator therefor,"A hemostatic clip which permits selection of the clamping pressure applied by the clip to tissue is of single piece plastic construction and C-shaped configuration. A transversely extending region of reduced thickness at the center of the mid-portion of the clip defines the hinge axis of the clip. Cooperating latching members extend from the mid-portion on opposite sides of the reduced thickness region. A dispenser for the clips has a magazine for storing a series of clips, a dispensing mechanism for advancing clips from the magazine, and an applicator tip receiving the advanced clip and having adjustably spaced plates for determining the degree to which the clip is closed.",FRAZEE JOHN G;;MALCOLM ROGER J,FRAZEE JOHN G;;MALCOLM ROGER J,,https://lens.org/026-771-146-025-534,Granted Patent,yes,6,28,1,2,0,A61B17/128;;A61B17/128;;Y10S227/902;;Y10S227/902,A61B17/128,606/213;;606/157;;227/902,0,0,,,,EXPIRED
9,US,A,US 5032127 A,116-751-203-232-885,1991-07-16,1991,US 48990090 A,1990-03-07,US 48990090 A,1990-03-07,Hemostatic clip and applicator therefor,"A hemostatic clip applicator tool includes a replacable magazine for storing a series of clips, a dispensing mechanism for advancing clips from the magazine, and an applicator tip which receives the advanced clip and closes the same to a controlled degree of clamping pressure.",FRAZEE JOHN G;;MALCOLM ROGER J,FRAZEE JOHN G;;MALCOLM ROGER J,,https://lens.org/116-751-203-232-885,Granted Patent,yes,4,280,1,2,0,A61B17/128;;A61B17/128,A61B17/128,606/143;;606/139,0,0,,,,EXPIRED
10,ZA,B,ZA 904583 B,121-728-906-978-988,1992-05-27,1992,ZA 904583 A,1990-06-13,US 36604689 A,1989-06-14,LEUKOTRIENE ANTAGONISTS,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,GLEASON JOHN GERALD;;FRAZEE JAMES SIMPSON;;JAMES SIMPSON FRAZEE;;JOHN GERALD GLEASON;;HALL RALPH FLOYD;;RALPH FLOYD HALL,,https://lens.org/121-728-906-978-988,Granted Patent,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/16;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
11,ZA,B,ZA 884272 B,118-733-511-383-574,1989-06-28,1989,ZA 884272 A,1988-06-15,US 6658887 A,1987-06-24,LEUKOTRIENE ANTAGONISTS,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SHMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;JAMES SIMPSON FRAZEE;;GLEASON JOHN GERALD;;JOHN GERALD GLEASON;;HALL RALPH FLOYD;;RALPH FLOYD HALL,,https://lens.org/118-733-511-383-574,Granted Patent,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;C07D239/28;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
12,PT,A,PT 94373 A,012-601-868-163-12X,1991-02-08,1991,PT 9437390 A,1990-06-12,US 36604689 A,1989-06-14,PROCESSO DE PREPARACAO DE COMPOSTOS DE ACIDO ALCANOICO COM SUBSTITUINTES FENILO E HETEROARILTIO E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,GLEASON JOHN GERALD;;FRAZEE JAMES SIMPSON;;HALL RALPH FLOYD,,https://lens.org/012-601-868-163-12X,Patent Application,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/22;;A61K31/16;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,DISCONTINUED
13,CA,C,CA 1334200 C,037-346-967-379-016,1995-01-31,1995,CA 565502 A,1988-04-29,US 6658887 A,1987-06-24,LEUKOTRIENE ANTAGONISTS,"This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, processes for the preparation thereof, and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions. The compounds of the present invention are of Formula (I) as further defined herein: <IMG> (I)",SMITHKLINE BECKMAN CORP,FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F,,https://lens.org/037-346-967-379-016,Granted Patent,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,C07D239/28;;A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,D12600251    M;;1670179    S;;26002911   S;;2600312    S;;26003576   S;;26004725   S;;26004781   S;;26005091   S,0,0,,,,EXPIRED
14,NZ,A,NZ 234009 A,032-767-844-275-78X,1993-02-25,1993,NZ 23400990 A,1990-06-11,US 36604689 A,1989-06-14,LEUKOTRIENE ANTAGONISTS,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/032-767-844-275-78X,Patent Application,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/16;;A61K31/352;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,PENDING
15,AU,B2,AU 645253 B2,156-212-437-086-372,1994-01-13,1994,AU 1990/056902 A,1990-06-08,US 36604689 A,1989-06-14,Leukotriene antagonists,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/156-212-437-086-372,Granted Patent,no,2,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/16;;A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
16,PT,A,PT 87615 A,072-157-134-765-250,1988-06-01,1988,PT 8761588 A,1988-05-30,US 6658887 A,1987-06-24,PROCESS FOR THE PREPARATION OF LEUKOTRIENE ANTAGONISTS AND OF PHARMACEUTICAL COMPOUNDS,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/072-157-134-765-250,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;C07D239/28;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
17,CN,A,CN 1030074 A,183-652-757-623-980,1989-01-04,1989,CN 88103724 A,1988-06-15,US 6658887 A,1987-06-24,LEUKOTRIENE ANTAGONISTS,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RELPH FLOYD,,https://lens.org/183-652-757-623-980,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,C07D239/28;;A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,DISCONTINUED
18,DK,D0,DK 327088 D0,157-837-791-900-556,1988-06-15,1988,DK 327088 A,1988-06-15,US 6658887 A,1987-06-24,LEUKOTRIENANTAGONISTER,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/157-837-791-900-556,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;C07D239/28;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,DISCONTINUED
19,HU,B,HU 201521 B,136-257-909-325-444,1990-11-28,1990,HU 304588 A,1988-06-14,US 6658887 A,1987-06-24,PROCESS FOR PRODUCING BENZENETHIO OR BENZYLSULFONYL DERIVATIVES WITH LEUKOTRIENE ANTAGONIST ACTIVITY AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/136-257-909-325-444,Granted Patent,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;C07D239/28;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
20,NZ,A,NZ 225021 A,092-554-992-081-474,1991-02-26,1991,NZ 22502188 A,1988-06-14,US 6658887 A,1987-06-24,LEUKOTRIENE ANTAGONISTS AND MEDICAMENTS,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/092-554-992-081-474,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07D239/28;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,DISCONTINUED
21,HU,A,HU T47242 A,165-773-616-292-063,1989-02-28,1989,HU 304588 A,1988-06-14,US 6658887 A,1987-06-24,PROCESS FOR PRODUCING PHENYLTHIO OR BENZOPYRANTHIO DERIVATIVES WITH LEUKOTRIENE-ANTAGONIST EFFECT AND PHARMACEUTICALS COMPRISING SAME,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F,,https://lens.org/165-773-616-292-063,Unknown,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;C07D239/28;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
22,DK,T3,DK 0403249 T3,030-778-911-787-146,1994-05-24,1994,DK 90306438 T,1990-06-13,US 36604689 A,1989-06-14,Leukotrienantagonister,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/030-778-911-787-146,Granted Patent,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/41;;A61K31/16;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
23,EP,A1,EP 0403249 A1,066-194-415-537-452,1990-12-19,1990,EP 90306438 A,1990-06-13,US 36604689 A,1989-06-14,Leukotriene antagonists.,"Compounds represented by the following structural formula (I):
   wherein q is O or 2; 
R₁ is (L) a -(CH₂) b -(T) c -M 
a is 0 or 1; 
b is 3 to 14; 
c is 0 or 1; 
L and T are independently oxygen or CH₂; 
M is C₁₋₄ alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF₃, alkoxy, alkyl, methylthio, or trifluoromethylthio;                   
Y is (CHX)(CH₂) p -Z wherein 
Z is COR₃, or tetrazolyl; in which 
R₃ is OH, NH₂, aryloxy, or C₁₋₆ alkoxy; 
p is 0, 1 or 2; 
X is OH, or alkoxy; 
R is -(CH₂) p -W; 
d is 0 to 6; 
W is phenyl substituted with B, C, or D; 
B is-(CH₂) p -V wherein p is 0 to 6 and V is COR₃, SO₃H, SO₂H, SO₂NH₂, COCH₂OH, CHOHCH₂OH, or tetrazolyl, with R₃ as defined above; 
C and D are independently selected from H, OH, F, Cl, Br, CF₃, alkyl, alkoxy, methylthio, trifluoromethylthio, NO₂, NH₂, NHalkyl, or CalkylCO-; or 
pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.  ",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/066-194-415-537-452,Patent Application,yes,2,3,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/41;;A61K31/16;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
24,WO,A1,WO 1999/004849 A1,084-791-145-807-480,1999-02-04,1999,US 9815353 W,1998-07-24,US 90096797 A,1997-07-25,RETROPERFUSION CATHETER APPARATUS AND METHOD,"A catheter (10) to retro-perfuse a venous junction formed by first, second and third veins includes an elongate tube having a plurality of channels (92) including a through lumen (101) extending between a proximal end, and a distal end. A proximal balloon (38) is inflatable to partially occlude the third vein while a distal balloon (41) is inflatable to partially occlude the second vein. An operative region of the catheter between the first, and second balloons is adapted to pressurize the venous junction with arterial blood to produce retrograde blood flow in the first vein.",UNIV CALIFORNIA,FRAZEE JOHN G;;CORNETT DAVID C;;EVANS SCOTT M,,https://lens.org/084-791-145-807-480,Patent Application,yes,3,19,2,2,0,A61M25/1011;;A61M25/1011;;A61M2025/0079;;A61M2025/0079;;A61M2025/105;;A61M2025/105;;A61M2025/1052;;A61M2025/1052;;A61M2210/0693;;A61M2210/0693,A61F2/958;;A61M25/14,,0,0,,,,PENDING
25,WO,A1,WO 1995/023790 A1,146-077-536-200-474,1995-09-08,1995,US 9502606 W,1995-03-03,GB 9404046 A,1994-03-03,CYTOKINE INHIBITING IMIDAZOLE SUBSTITUTED HYDROXAMIC ACID DERIVATIVES,"The present invention relates to a series of novel imidazole substituted hydroxamic acid derivatives, and compositions useful thereof as inhibitors of matrix degrading metalloproteinases, in particular collagenase.",SMITHKLINE BEECHAM CORP;;FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;METCALF BRIAN WALTER,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;METCALF BRIAN WALTER,,https://lens.org/146-077-536-200-474,Patent Application,yes,4,28,5,6,0,A61P1/02;;A61P1/04;;A61P17/00;;A61P19/10;;A61P29/00;;A61P35/02;;A61P43/00;;C07D233/64;;C07D233/68,A61K31/415;;A61P1/02;;A61P1/04;;A61P17/00;;A61P19/10;;A61P29/00;;A61P35/02;;A61P43/00;;C07D233/54;;C07D233/64;;C07D233/68,,1,0,,,See also references of EP 0748313A4,PENDING
26,CA,A,CA 989807 A,159-927-716-371-780,1976-05-25,1976,CA 155141 A,1972-10-30,US 23646072 A,1972-04-26,SUPPORTED COPPER CHROMITE CATALYST,,GRACE W R & CO,FRAZEE JOHN R;;MARTIN BRIAN R;;BRUNDRETT CHARLES P,,https://lens.org/159-927-716-371-780,Granted Patent,no,0,0,8,8,0,B01J23/868;;B01J23/868,B01J23/86,252-83,0,0,,,,EXPIRED
27,DE,A1,DE 2311114 A1,020-777-108-117-998,1973-10-31,1973,DE 2311114 A,1973-03-06,US 23646072 A,1972-04-26,VERFAHREN ZUR HERSTELLUNG EINES AUF TRAEGER AUFGEBRACHTEN KUPFERCHROMITKATALYSATORS,,GRACE W R & CO,FRAZEE JOHN ROBERT;;MARTIN BRIAN READ;;BRUNDRETT CHARLES PHILIPP,,https://lens.org/020-777-108-117-998,Patent Application,no,1,5,8,8,0,B01J23/868;;B01J23/868,B01J23/86,,0,0,,,,EXPIRED
28,PT,B,PT 87615 B,065-270-578-903-731,1992-09-30,1992,PT 8761588 A,1988-05-30,US 6658887 A,1987-06-24,PROCESSO DE PREPARACAO DE ANTAGONISTAS DO LEUCOTRIENO E DE COMPOSICOES FARMACEUTICASD,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BEECHAM CORP,GLEASON JOHN GERALD;;FRAZEE JAMES SIMPSON;;HALL RALPH FLOYD,,https://lens.org/065-270-578-903-731,Granted Patent,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;C07D239/28;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
29,NO,L,NO 882607 L,099-705-712-150-085,1988-12-27,1988,NO 882607 A,1988-06-14,US 6658887 A,1987-06-24,FREMGANGSMAATE FOR FREMSTILLING AV LEUKOTRIENANTAGONISTER.,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/099-705-712-150-085,Abstract,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;C07D239/28;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,DISCONTINUED
30,CA,A1,CA 2018437 A1,097-521-237-656-263,1990-12-14,1990,CA 2018437 A,1990-06-07,US 36604689 A,1989-06-14,LEUKOTRIENE ANTAGONISTS,"This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, processes for the preparation thereof, and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.",FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F,FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F,,https://lens.org/097-521-237-656-263,Patent Application,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/16;;A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,D226005091   M;;1670179    S;;2600312    S;;26003294   S;;26003576   S;;26004738   S;;26005143   S,0,0,,,,DISCONTINUED
31,FI,A0,FI 882866 A0,169-191-744-040-632,1988-06-15,1988,FI 882866 A,1988-06-15,US 6658887 A,1987-06-24,LEUKOTRIENANTAGONISTER.,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/169-191-744-040-632,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;C07D239/28;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,DISCONTINUED
32,EP,A1,EP 0748313 A1,196-487-517-952-000,1996-12-18,1996,EP 95912688 A,1995-03-03,GB 9404046 A;;US 9502606 W,1994-03-03,CYTOKINE INHIBITING IMIDAZOLE SUBSTITUTED HYDROXAMIC ACID DERIVATIVES,,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;METCALF BRIAN WALTER,,https://lens.org/196-487-517-952-000,Patent Application,yes,0,0,5,6,0,A61P1/02;;A61P1/04;;A61P17/00;;A61P19/10;;A61P29/00;;A61P35/02;;A61P43/00;;C07D233/64;;C07D233/68,A61K31/415;;A61P1/02;;A61P1/04;;A61P17/00;;A61P19/10;;A61P29/00;;A61P35/02;;A61P43/00;;C07D233/54;;C07D233/64;;C07D233/68,,0,0,,,,DISCONTINUED
33,AT,T1,AT E104955 T1,035-801-188-989-412,1994-05-15,1994,AT 90306438 T,1990-06-13,US 36604689 A,1989-06-14,LEUKOTRIENANTAGONISTEN.,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/035-801-188-989-412,Granted Patent,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/16;;A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,DISCONTINUED
34,US,A,US 5314918 A,090-272-900-212-070,1994-05-24,1994,US 86415692 A,1992-04-02,US 86415692 A;;US 6658887 A;;US 36604689 A,1987-06-24,Leukotriene antagonists,"This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, processes for the preparation thereof, and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F,,https://lens.org/090-272-900-212-070,Granted Patent,yes,8,7,2,42,0,C07C317/46;;C07C317/46;;C07C323/00;;C07C323/00;;C07C323/56;;C07C323/56;;C07C323/62;;C07C323/62;;C07D311/24;;C07D311/24,A61K31/15;;A61K31/19;;C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24,514/570;;514/438;;514/457;;514/544;;544/335;;546/335;;546/337;;546/342;;548/253;;549/77;;549/79;;549/401;;549/496;;560/9;;560/11;;560/17;;560/18;;562/429;;562/431;;562/432,4,0,,,"Derwent Patent Abstract 84 014267/03 of Japanese Patent Appln. 58/206556A, published Dec. 1, 1983.;;Derwent Patent Abstract 85 026589/05 of European Patent Appln. 132336A, published Jan. 30, 1985.;;Chemical Abstracts 96(17): 143290n, (1981).;;Chemical Abstracts 94(9): 64755y, (1981).",EXPIRED
35,DE,D1,DE 69008428 D1,153-536-569-702-482,1994-06-01,1994,DE 69008428 T,1990-06-13,US 36604689 A,1989-06-14,Leukotrienantagonisten.,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/153-536-569-702-482,Granted Patent,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/16;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
36,FI,A,FI 882866 A,178-021-380-045-268,1988-12-25,1988,FI 882866 A,1988-06-15,US 6658887 A,1987-06-24,LEUKOTRIENANTAGONISTER.,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/178-021-380-045-268,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;C07D239/28;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,DISCONTINUED
37,DK,A,DK 327088 A,171-573-245-213-24X,1988-12-25,1988,DK 327088 A,1988-06-15,US 6658887 A,1987-06-24,LEUKOTRIENANTAGONISTER,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/171-573-245-213-24X,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;A61K31/215;;C07D239/28;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,DISCONTINUED
38,US,A,US 5665753 A,040-754-602-351-521,1997-09-09,1997,US 70252896 A,1996-09-03,US 70252896 A;;GB 9404046 A;;US 9502606 W,1994-03-03,Cytokine inhibiting imidazole substituted hydroxamic acid derivatives,"The present invention relates to a series of novel imidazole substituted hydroxamic acid derivatives, and compositions useful thereof as inhibitors of matrix degrading metalloproteinases, in particular collagenase.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;METCALF BRIAN WALTER,SMITHKLINE BEECHAM CORPORATION (1995-03-07),https://lens.org/040-754-602-351-521,Granted Patent,yes,4,15,1,6,0,C07D233/64;;C07D233/68;;C07D233/64;;C07D233/68,C07D233/54;;C07D233/68,514/394;;514/396;;548/302.7;;548/304.4;;548/335.1;;548/338.1;;548/343.5,0,0,,,,EXPIRED
39,AU,A,AU 1990/056902 A,140-161-454-157-883,1990-12-20,1990,AU 1990/056902 A,1990-06-08,US 36604689 A,1989-06-14,LEUKOTRIENE ANTAGONISTS,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/140-161-454-157-883,Patent Application,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/16;;A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
40,NO,D0,NO 882607 D0,024-311-095-301-446,1988-06-14,1988,NO 882607 A,1988-06-14,US 6658887 A,1987-06-24,FREMGANGSMAATE FOR FREMSTILLING AV LEUKOTRIENANTAGONISTER.,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/024-311-095-301-446,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;C07D239/28;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,DISCONTINUED
41,ES,T3,ES 2063271 T3,050-403-224-207-263,1995-01-01,1995,ES 90306438 T,1990-06-13,US 36604689 A,1989-06-14,ANTAGONISTAS DE LEUCOTRIENOS.,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/050-403-224-207-263,Granted Patent,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/16;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
42,EP,A4,EP 0748313 A4,162-346-982-254-563,1997-06-11,1997,EP 95912688 A,1995-03-03,GB 9404046 A;;US 9502606 W,1994-03-03,CYTOKINE INHIBITING IMIDAZOLE SUBSTITUTED HYDROXAMIC ACID DERIVATIVES,,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;METCALF BRIAN WALTER,,https://lens.org/162-346-982-254-563,Search Report,no,3,0,5,6,0,A61P1/02;;A61P1/04;;A61P17/00;;A61P19/10;;A61P29/00;;A61P35/02;;A61P43/00;;C07D233/64;;C07D233/68,A61K31/415;;A61P1/02;;A61P1/04;;A61P17/00;;A61P19/10;;A61P29/00;;A61P35/02;;A61P43/00;;C07D233/54;;C07D233/64;;C07D233/68,,1,0,,,See also references of WO 9523790A1,DISCONTINUED
43,AU,A,AU 1988/017595 A,123-713-068-804-073,1989-01-05,1989,AU 1988/017595 A,1988-06-10,US 6658887 A,1987-06-24,LEUKOTRIENE ANTAGONISTS,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/123-713-068-804-073,Patent Application,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,C07D239/28;;A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
44,MX,A,MX 9203754 A,181-031-741-407-867,1992-09-30,1992,MX 9203754 A,1992-06-29,US 6658887 A;;US 36604689 A;;US 86415692 A,1987-06-24,ANTAGONISTAS DE LEUCOTRIENO.,,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/181-031-741-407-867,Patent Application,no,0,0,2,42,0,C07C317/46;;C07C317/46;;C07C323/00;;C07C323/00;;C07C323/56;;C07C323/56;;C07C323/62;;C07C323/62;;C07D311/24;;C07D311/24,A61K31/15;;A61K31/19;;C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24,,0,0,,,,PENDING
45,AT,T1,AT E68176 T1,176-954-186-443-467,1991-10-15,1991,AT 88305188 T,1988-06-07,EP 88305188 A;;US 6658887 A,1987-06-24,LEUKOTRIENANTAGONISTEN.,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/176-954-186-443-467,Granted Patent,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,C07D239/28;;A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
46,EP,B1,EP 0296732 B1,111-140-973-534-48X,1991-10-09,1991,EP 88305188 A,1988-06-07,US 6658887 A,1987-06-24,LEUKOTRIENE ANTAGONISTS,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BEECHAM CORPORATION,"FRAZEE, JAMES SIMPSON;;GLEASON, JOHN GERALD;;HALL, RALPH FLOYD",SMITHKLINE BEECHAM CORPORATION (1991-06-19),https://lens.org/111-140-973-534-48X,Granted Patent,yes,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;C07D239/28;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,1,1,084-208-214-788-981,10.1021/jm00389a001;;3035179,"JOURNAL OF MEDICINAL CHEMISTRY, Vol. 30, no.6, June 1987, pages 959-961, Am. Chem. Soc., US; J.G. GLEASON et al.: ""High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-((2-carboxyethyl)trio)-3-(2-(8-phenyl-octyl)phenyl)propanoic acid""",EXPIRED
47,US,A,US 5908407 A,106-985-174-982-271,1999-06-01,1999,US 90096797 A,1997-07-25,US 90096797 A,1997-07-25,Retroperfusion catheter apparatus and method,"A catheter for retroprofusing a venous junction formed by first, second and third veins, includes an elongate tube having a plurality of channels including a through-lumen extending between a proximal end and a distal end. A proximal balloon is inflatable to partially occlude the third vein, while a distal balloon is inflatable to partially occlude the second vein. An operative region of the catheter between the first and second balloons is adapted to pressurize the venous junction with arterial blood to produce retrograde blood flow in the first vein.",NEUROPERFUSION INC,FRAZEE JOHN G;;CORNETT DAVID C;;EVANS SCOTT M,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2000-02-28);;ALSIUS CORPORATION (2000-03-22);;ZOLL CIRCULATION INC (2009-05-04);;NEUROPERFUSION INC (1997-07-18),https://lens.org/106-985-174-982-271,Granted Patent,yes,39,254,2,2,0,A61M25/1011;;A61M25/1011;;A61M2025/0079;;A61M2025/0079;;A61M2025/105;;A61M2025/105;;A61M2025/1052;;A61M2025/1052;;A61M2210/0693;;A61M2210/0693,A61F2/958;;A61M25/14,604/101;;604/49;;604/53;;604/65;;604/99;;606/194,0,0,,,,EXPIRED
48,DE,T2,DE 69008428 T2,126-753-212-986-699,1994-11-24,1994,DE 69008428 T,1990-06-13,US 36604689 A,1989-06-14,Leukotrienantagonisten.,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/126-753-212-986-699,Granted Patent,no,0,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/16;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
49,EP,A1,EP 0296732 A1,015-703-593-308-639,1988-12-28,1988,EP 88305188 A,1988-06-07,US 6658887 A,1987-06-24,Leukotriene antagonists.,"Compounds of formula:
  in which, inter alia q is 0 to 2, R, is (L) a -(CH 2 ) b -(T) c -M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH 2 ; and M is C 1-4  alkyl, ethynyl, CF 3 , isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R 2  and A are H, CF 3 , alkyl, alkoxy, halogen, OH, N0 2 , or NH 2  or R 1  and A are H and R 2  is (L) a -(CH 2 ) b -(T) c -M as above; y is COR 3  or (CHX) n (CH 2 )p-Z wherein R 3  is OH, NH 2 , aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR 3  or tetrazolyl; R is (CR 5 R 6 ) d W, R 5  and R 6  are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,SMITHKLINE BEECHAM CORPORATION (1991-06-19),https://lens.org/015-703-593-308-639,Patent Application,yes,1,11,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;C07D239/28;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,37,24,056-748-662-787-669;;028-611-841-459-422;;007-687-860-490-459;;075-988-636-594-275;;098-901-999-220-600;;002-280-576-255-084;;093-906-651-665-597;;023-953-106-357-145;;063-631-831-507-539;;019-529-540-354-986;;023-887-929-339-471;;047-316-252-378-744;;057-140-080-278-54X;;032-695-658-961-081;;050-700-464-921-088;;083-234-247-528-986;;105-203-650-769-864;;022-997-050-730-999;;113-112-838-044-626;;158-181-426-255-955;;008-139-620-328-830;;069-619-821-582-507;;028-611-841-459-422;;052-868-995-619-736,pmc349833;;10.1073/pnas.77.7.4354;;6933488;;10.1164/arrd.1982.126.3.449;;7125334;;10.1016/0090-6980(84)90145-x;;10.1056/nejm198406213102502;;6328300;;10.1213/00000539-198603000-00014;;3006549;;10.1111/j.1398-9995.1985.tb02680.x;;2996379;;10.1001/archopht.1986.01050170112033;;3010919;;6088617;;10.1016/0091-6749(84)90144-1;;10.1111/1523-1747.ep12531738;;6296237;;6278136;;3002383;;10.1016/0006-2952(86)90502-2;;6722998;;10.1161/01.res.54.5.492;;3537451;;10.1038/ki.1986.210;;2988310;;4048937;;10.1126/science.4048937;;pmc319678;;6267608;;10.1073/pnas.78.6.3887;;10.1038/293103a0;;6115319;;3010332;;10.1016/0262-1746(86)90052-1;;2875632;;10.1007/bf01965001;;2999234;;3515429;;10.1016/0090-6980(86)90054-7;;10.1016/0002-9610(83)90166-6;;6849496;;10.1164/arrd.1982.126.3.449;;7125334;;10.1021/jo00401a018,"LEFT, A.M., BIOCHEMICAL, vol. 35, no. 2, 1986, pages 123 - 127;;DRAZEN, J.M. ET AL., PROC. NAT'1. ACAD. SCI. USA, vol. 77, no. 7, 1980, pages 4354 - 4358;;MAROM, Z. ET AL., AM. REV. RESPIR. DIS., vol. 126, 1982, pages 449 - 451;;ZAKRZEWSKI, J.T. ET AL., PROSTAGLANDINS, vol. 28, no. 5, 1984, pages 641;;CRETICOS, P.S. ET AL., NEW ENGLAND J. OF MED., vol. 310, no. 25, 1984, pages 1626 - 1629;;SNAPPER, J.R. ET AL., ABSTRACTS OF INT'L CONF. ON PROSTAGLANDINS AND RELATED COMP., June 1986 (1986-06-01), pages 495;;MATTHAY, M. ET AL., J. CLIN. IMMUNOL., vol. 4, 1981, pages 479 - 483;;SWERDLOW, B.N. ET AL., ANESTH. ANALG., vol. 65, 1986, pages 306 - 308;;BISGAARD, H. ET AL., ALLERQY, vol. 40, 1985, pages 417 - 423;;PARKER, J.A. ET AL., ARCH OPHTHALMOL, vol. 104, 1986, pages 722 - 724;;FORD-HUTCHINSON, J. ALLERQY CLIN. IMMUNOL., vol. 74, 1984, pages 437 - 440;;SOTER ET AL., J. CLIN INVEST DERMATOL, vol. 80, 1983, pages 115 - 119;;BURKE, J.A. ET AL., J. PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 221, no. 1, 1982, pages 235 - 241;;LEFER, A.M., BIOCHEMICAL PHARMACOLOGY, vol. 35, no. 2, 1986, pages 123 - 127;;BADR, K.R. ET AL., CIRCULATION RESEARCH, vol. 54, no. 5, 1984, pages 4F2 - 499;;BADR, K.F. ET AL., KIDNEY INTERNATIONAL, vol. 30, 1986, pages 474 - 480;;BADR, K.F. ET AL., KIDNEY INTERNATIONAL, vol. 29, no. 1, 1986, pages 328;;DUNN, M.J. ET AL., KIDNEY INTERNATIONAL, vol. 27, no. 1, 1985, pages 256;;FOEGH, M.L. ET AL., ADVANCES IN PROSTAGLANDIN, THROMBOXANE, AND LEUKOTRIENE RESEARCH, vol. 13, 1985, pages 209 - 217;;COFFMAN, T.M. ET AL., KIDNEY INTERNATIONAL, vol. 29, no. 1, 1986, pages 332;;DENZLINGER, C. ET AL., SCIENCE, vol. 230, 1985, pages 330 - 332;;DAHLEN, S.E. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, no. 6, 1981, pages 3887 - 3891;;LEWIS, R.A. ET AL., NATURE, vol. 293, 1981, pages 103 - 108;;DENZLINGER, C. ET AL., PROSTAGLANDINS LEUKOTRIENES AND MEDICINE, vol. 21, 1986, pages 321 - 322;;PESKAR, B.M. ET AL., AGENTS AND ACTIONS, vol. 18, 1986, pages 381 - 383;;ROLA-PLESZCZYNSKI, M. ET AL., J. OF IMMUN., vol. 135, no. 6, 1985, pages 3958 - 3961;;WISCHNEWSKY, G.G. ET AL., ANTICANCER RES., vol. 5, no. 6, 1985, pages 639;;DREYLING, K.W. ET AL., BRITISH J. PHARMACOLOGY, vol. 88, 1986, pages 236P;;PESKAR, B.M. ET AL., PROSTAGLANDINS, vol. 31, no. 2, 1986, pages 283 - 293;;OGLE, C.W. ET AL., IRCS MED. SCI., vol. 14, 1986, pages 114 - 115;;CLAYTON, J.K. ET AL., PROCEEDINGS OF THE BPS, vol. 573P, 17 December 1994 (1994-12-17);;GAZZANIGA, P.P. ET AL., ABSTRACTS INT'L CONF. ON PROSTAGLANDINS AND RELATED COMP., June 1986 (1986-06-01), pages 121;;DOTY, J.E. ET AL., AMER. J. OF SURGERY, vol. 145, 1983, pages 54 - 61;;MAROM, Z. ET AL., AMER. REV. RESPIR. DIS., vol. 126, 1982, pages 449 - 451;;MEYERS ET AL., J. ORG. CHEM., vol. 43, 1978, pages 1372;;HAGIHARA ET AL., SYNTHESIS, vol. 627, 1980;;WILEY, P.F., J. ORG. CHEM., vol. 16, 1951, pages 812",EXPIRED
50,EP,B1,EP 0403249 B1,065-926-343-854-25X,1994-04-27,1994,EP 90306438 A,1990-06-13,US 36604689 A,1989-06-14,Leukotriene antagonists.,"Compounds represented by the following structural formula (I): <CHEM> wherein q is O or 2; R1 is (L)a-(CH2)b-(T)c-M a is 0 or 1; b is 3 to 14; c is 0 or 1; L and T are independently oxygen or CH2; M is C1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF3, alkoxy, alkyl, methylthio, or trifluoromethylthio; Y is (CHX)(CH2)p-Z wherein Z is COR3, or tetrazolyl; in which R3 is OH, NH2, aryloxy, or C1-6 alkoxy; p is 0, 1 or 2; X is OH, or alkoxy; R is -(CH2)p-W; d is 0 to 6; W is phenyl substituted with B, C, or D; B is-(CH2)p-V wherein p is 0 to 6 and V is COR3, SO3H, SO2H, SO2NH2, COCH2OH, CHOHCH2OH, or tetrazolyl, with R3 as defined above; C and D are independently selected from H, OH, F, Cl, Br, CF3, alkyl, alkoxy, methylthio, trifluoromethylthio, NO2, NH2, NHalkyl, or CalkylCO-; or pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/065-926-343-854-25X,Granted Patent,yes,2,0,18,42,0,C07C317/46;;C07C323/56;;C07C323/62;;C07D311/24;;A61P43/00;;C07C327/08,A61K31/19;;A61K31/215;;A61K31/22;;A61K31/235;;A61K31/24;;A61K31/35;;A61K31/352;;A61K31/16;;A61K31/41;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/505;;A61P43/00;;C07C317/44;;C07C317/46;;C07C323/56;;C07C323/60;;C07C323/62;;C07C323/64;;C07C323/66;;C07C323/67;;C07D213/32;;C07D239/28;;C07D239/38;;C07D257/04;;C07D311/24,,0,0,,,,EXPIRED
51,AU,B2,AU 620037 B2,171-300-587-770-800,1992-02-13,1992,AU 1988/017595 A,1988-06-10,US 6658887 A,1987-06-24,LEUKOTRIENE ANTAGONISTS,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/171-300-587-770-800,Granted Patent,no,1,2,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,C07D239/28;;A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
52,DE,D1,DE 3865373 D1,186-150-027-265-762,1991-11-14,1991,DE 3865373 T,1988-06-07,US 6658887 A,1987-06-24,LEUKOTRIENANTAGONISTEN.,"Compounds of formula: <CHEM> in which, inter alia q is 0 to 2, R1 is (L)a-(CH2)b-(T)c-M wherein a and ca are 0 or 1, b is 3 to 14, L and T are independently O, S or CH2; and M is C1-4 alkyl, ethynyl, CF3, isopropenyl, furanyl, thienyl, cyclohexyl or optionally substituted phenyl; R2 and A are H, CF3, alkyl, alkoxy, halogen, OH, NO2, or NH2 or R1 and A are H and R2 is (L)a-(CH2)b-(T)c-M as above; y is COR3 or (CHX)n(CH2)p-Z wherein R3 is OH, NH2, aryloxy or alkoxy, n is 0 or 1, p is 0, 1 or 2; X is H, OH, alkyl, alkoxy or F, Z is COR3 or tetrazolyl; R is (CR5R6)dW, R5 and R6 are H or alkyl and W is an optionally substituted phenyl, pyridyl or pyrimidiyl group, intermediates and processes for their preparation and their use in therapy as leukotriene antagonists.",SMITHKLINE BECKMAN CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/186-150-027-265-762,Granted Patent,no,0,0,21,42,0,C07C323/00;;C07D311/24;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;A61P9/12,A61K31/165;;A61K31/19;;A61K31/215;;A61K31/33;;C07D239/28;;A61K31/41;;A61K31/505;;A61P9/12;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07C67/00;;C07C313/00;;C07C317/04;;C07C317/44;;C07C317/46;;C07C317/48;;C07C321/04;;C07C323/00;;C07C323/56;;C07C323/60;;C07C323/65;;C07C323/66;;C07C323/67;;C07D239/38;;C07D257/04;;C07D311/24;;C07D311/66;;C07D521/00,,0,0,,,,EXPIRED
53,EP,A2,EP 0382669 A2,108-925-537-873-962,1990-08-16,1990,EP 90480002 A,1990-01-03,US 30829289 A,1989-02-09,Method of operating a full-duplex conversation in a communication network.,"A method for the full duplex exchange of data via a conversation between a pair of transaction programs (TP) over a network in which any transaction program which requests a confirmation of previously sent data inhibits the further transmission of data until a response to the request is received and a transaction program which receives a request for confirmation will inhibit the receipt of data until a response to the confirmation request is sent. In addition, when a transaction program (TP) attempts to terminate a conversation a definite response is requested and the response to the termination will be queued behind any data which remains to be sent so as to purge that data from the network.  ",IBM,FERREE MARSHA ELLEN;;GRAY JAMES PEYTON;;POZEFSKY MARK;;WILDER JOHN FRAZEE,,https://lens.org/108-925-537-873-962,Patent Application,yes,0,1,5,5,0,G06F9/466;;H04L69/00;;G06F9/466;;H04L69/00,H04L5/14;;G06F9/46;;H04L29/00;;H04L29/08,,0,0,,,,DISCONTINUED
54,EP,A3,EP 0382669 A3,013-662-323-089-930,1992-07-01,1992,EP 90480002 A,1990-01-03,US 30829289 A,1989-02-09,METHOD OF OPERATING A FULL-DUPLEX CONVERSATION IN A COMMUNICATION NETWORK,"A method for the full duplex exchange of data via a conversation between a pair of transaction programs (TP) over a network in which any transaction program which requests a confirmation of previously sent data inhibits the further transmission of data until a response to the request is received and a transaction program which receives a request for confirmation will inhibit the receipt of data until a response to the confirmation request is sent. In addition, when a transaction program (TP) attempts to terminate a conversation a definite response is requested and the response to the termination will be queued behind any data which remains to be sent so as to purge that data from the network.  ",INTERNATIONAL BUSINESS MACHINES CORPORATION,"FERREE, MARSHA ELLEN;;GRAY, JAMES PEYTON;;POZEFSKY, MARK;;WILDER, JOHN FRAZEE",,https://lens.org/013-662-323-089-930,Search Report,yes,1,0,5,5,0,G06F9/466;;H04L69/00;;G06F9/466;;H04L69/00,H04L5/14;;G06F9/46;;H04L29/00;;H04L29/08,,4,1,003-119-709-045-335,10.1109/66.44614,"TECHNISCHE RUNDSCHAU. vol. 77, no. 22, May 1985, BERN CH pages 76 - 84; K. BIDLINGMAIER: 'Kommunikationsstandards Normung der höheren Ebenen';;IEEE TRANSACTIONS ON SEMICONDUCTOR MANUFACTURING vol. 2, no. 4, November 1989, MICHIGAN, US pages 165 - 177; J.R. MOYNE ET AL.: 'A prototype SECS message service for communication in the semiconductor manufacturing environment';;A.S. TANENBAUM 'COMPUTER NETWORKS' 1988 , PRENTICE-HALL, INC. , NEW JERSEY, US;;G. JOSEPH 'An introduction to advanced program-to-program communication' November 1986 , IBM , RALEIGH, US",DISCONTINUED
55,ZA,B,ZA 914959 B,130-756-113-464-009,1992-06-24,1992,ZA 914959 A,1991-06-27,US 54525890 A,1990-06-28,QUINOLINYL SUBSTITUTED PHENYL/THIOALKANOIC ACID SUBSTITUTED PROPIONIC ACIDS,,SMITHKLINE BEECHAM CORP,COUSINS RUSSELL DONOVAN;;RUSSELL DONOVAN COUSINS;;GLEASON JOHN GERALD;;JOHN GERALD GLEASON;;FRAZEE JAMES SIMPSON;;JAMES SIMPSON FRAZEE;;HALL RALPH FLOYD;;RALPH FLOYD HALL,,https://lens.org/130-756-113-464-009,Granted Patent,no,0,0,10,10,0,A61P11/00;;A61P43/00;;C07D215/14;;C07D401/06;;C07D401/06;;C07D215/12;;C07D215/12;;C07D215/14;;C07D215/14;;C07D215/18;;C07D215/18,A61K31/47;;A61P11/00;;A61P43/00;;C07D215/12;;C07D215/14;;C07D215/18;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,0,0,,,,EXPIRED
56,PT,A,PT 98078 A,003-678-498-403-278,1993-06-30,1993,PT 9807891 A,1991-06-24,US 54525890 A,1990-06-28,PROCESSO DE PREPARACAO DE ACIDOS PROPIONICOS SUBSTITUIDOS COM ACIDO FENIL/TIOALCANOICO SUBSTITUIDO COM QUINOLINILO E DE COMPOSICOES FARMACEUTICAS,,SMITHKLINE BEECHAM CORP,COUSINS RUSSELL DONOVAN;;GLEASON JOHN GERALD;;FRAZEE JAMES SIMPSON;;HALL RALPH FLOYD,,https://lens.org/003-678-498-403-278,Patent Application,no,0,0,10,10,0,A61P11/00;;A61P43/00;;C07D215/14;;C07D401/06;;C07D401/06;;C07D215/12;;C07D215/12;;C07D215/14;;C07D215/14;;C07D215/18;;C07D215/18,A61K31/47;;A61P11/00;;A61P43/00;;C07D215/12;;C07D215/14;;C07D215/18;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,0,0,,,,DISCONTINUED
57,WO,A1,WO 1992/000279 A1,086-209-930-715-991,1992-01-09,1992,US 9104262 W,1991-06-14,US 54525890 A,1990-06-28,CHEMICAL COMPOUNDS,"This invention covers quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids leukotriene inhibitors having general formula (I), where the substituents are defined herein.",SMITHKLINE BEECHAM CORP,COUSINS RUSSELL DONOVAN;;FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/086-209-930-715-991,Patent Application,yes,3,0,10,10,0,A61P11/00;;A61P43/00;;C07D215/14;;C07D401/06;;C07D401/06;;C07D215/12;;C07D215/12;;C07D215/14;;C07D215/14;;C07D215/18;;C07D215/18,A61K31/47;;A61P11/00;;A61P43/00;;C07D215/12;;C07D215/14;;C07D215/18;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,1,0,,,See also references of EP 0536310A4,PENDING
58,MX,A,MX 2021008648 A,175-450-535-576-976,2021-08-19,2021,MX 2021008648 A,2019-08-29,US 201916252026 A;;IB 2019057297 W,2019-01-18,ULTRASONIC GAS METERS AND RELATED FLOWTUBES.,"An ultrasonic meter configured to operate in multiple classes is provided including a flowtube having an inlet at a first end and an outlet at a second end, opposite the first end; and first and second face to face transducers, the first transducer being positioned at the first end of the flowtube and the second transducer being positioned at the second end of the flowtube, wherein the first and second face to face transducers are positioned in line with flow through the ultrasonic meter. Related flowtubes are also provided herein.",SENSUS SPECTRUM LLC,HEALY DAVID;;SOKOL BENJAMIN JOHN;;MEANWELL HILARY JANE;;FRAZEE ERIC;;PATERSON CHARLIE,,https://lens.org/175-450-535-576-976,Patent Application,no,0,0,6,6,0,G01F1/662;;G01F1/662;;G01F15/002,G01F1/66,,0,0,,,,PENDING
59,US,A,US 4996214 A,071-663-075-272-215,1991-02-26,1991,US 54525890 A,1990-06-28,US 54525890 A,1990-06-28,Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof,This invention covers quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids leukotriene inhibitors having the following general formula ##STR1## where the substituents are defined herein.,SMITHKLINE BEECHAM CORP,COUSINS RUSSELL D;;FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F,SMITHKLINE BEECHAM CORPORATION (1990-06-27),https://lens.org/071-663-075-272-215,Granted Patent,yes,2,7,10,10,0,A61P11/00;;A61P43/00;;C07D215/14;;C07D401/06;;C07D401/06;;C07D215/12;;C07D215/12;;C07D215/14;;C07D215/14;;C07D215/18;;C07D215/18,A61K31/47;;A61P11/00;;A61P43/00;;C07D215/12;;C07D215/14;;C07D215/18;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,514/311;;514/314;;546/172;;546/174;;546/175,0,0,,,,EXPIRED
60,CN,A,CN 113574349 A,183-447-829-314-640,2021-10-29,2021,CN 201980089372 A,2019-08-29,US 201916252026 A;;IB 2019057297 W,2019-01-18,Ultrasonic gas meters and related flowtubes,"An ultrasonic meter configured to operate in multiple classes is provided including a flowtube having an inlet at a first end and an outlet at a second end, opposite the first end; and first and second face-to-face transducers, the first transducer being positioned at the first end of the flowtube and the second transducer being positioned at the second end of the flowtube, wherein the first and second face-to-face transducers are positioned in line with flow through the ultrasonic meter. Related flowtubes are also provided herein.",SENSUS SPECTRUM LLC,HEALY DAIRE;;SOKOL BENJAMIN JOHN;;MEANWELL HILARY JANE;;FRAZEE ERIC;;PATTERSON CLAIRE,,https://lens.org/183-447-829-314-640,Patent Application,no,7,0,6,6,0,G01F1/662;;G01F1/662;;G01F15/002,G01F1/66,,0,0,,,,PENDING
61,EP,A4,EP 0536310 A4,049-953-933-438-380,1993-02-05,1993,EP 91913413 A,1991-06-14,US 54525890 A,1990-06-28,CHEMICAL COMPOUNDS.,,SMITHKLINE BEECHAM CORP,COUSINS RUSSELL DONOVAN;;FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/049-953-933-438-380,Search Report,no,3,0,10,10,0,A61P11/00;;A61P43/00;;C07D215/14;;C07D401/06;;C07D401/06;;C07D215/12;;C07D215/12;;C07D215/14;;C07D215/14;;C07D215/18;;C07D215/18,A61K31/47;;A61P11/00;;A61P43/00;;C07D215/12;;C07D215/14;;C07D215/18;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,2,1,084-208-214-788-981,10.1021/jm00389a001;;3035179,"JOURNAL OF MEDICINAL CHEMISTRY. vol. 30, no. 6, 1987, WASHINGTON US pages 959 - 961 JH.G. GLEASON ET AL. 'High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-((2-carbox yethyl)thio)-3(2-(8-phenyloctyl)phenyl)pro panoic acid';;See also references of WO 9200279A1",DISCONTINUED
62,US,S,US D0864777 S,179-937-035-141-773,2019-10-29,2019,US 201829656581 F,2018-07-13,US 201829656581 F,2018-07-13,Flow tube,,SENSUS SPECTRUM LLC,SOKOL BENJAMIN JOHN;;HEALY DAVID;;FRAZEE ERIC;;MEANWELL HILARY JANE;;PATERSON CHARLIE,SENSUS SPECTRUM LLC (2018-07-09),https://lens.org/179-937-035-141-773,Design Right,no,3,0,2,2,0,,,1004;;D10/103,0,0,,,,ACTIVE
63,WO,A1,WO 1991/017149 A1,095-793-281-511-228,1991-11-14,1991,US 9102889 W,1991-04-26,US 51858390 A,1990-05-01,3-NAPHTHYL-3-CARBOXYALKYLTHIO OR OXY SUBSTITUTED ALKANOIC ACID LEUKOTRIENE ANTAGONISTS,This invention relates to alkanoic acid compounds having a naphthyl ring and thio substituents which are useful as leukotriene antagonists.,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;UZINSKAS IRENE NIJOLE,,https://lens.org/095-793-281-511-228,Patent Application,yes,3,4,6,6,0,A61P11/08;;A61P43/00;;C07D257/04;;C07C45/46;;C07C45/56;;C07C45/565;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C323/56,A61K31/16;;A61K31/18;;A61K31/185;;A61K31/19;;A61K31/215;;A61K31/27;;A61K31/275;;A61K31/34;;A61K31/341;;A61K31/415;;A61K31/425;;A61K31/426;;A61P11/08;;A61P43/00;;C07C45/46;;C07C45/56;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C261/04;;C07C317/44;;C07C323/56;;C07D213/00;;C07D233/64;;C07D257/04;;C07D277/22;;C07D277/24;;C07D277/26;;C07D307/38,,1,0,,,See also references of EP 0527175A4,PENDING
64,CA,A1,CA 2081480 A1,107-232-709-427-478,1991-11-02,1991,CA 2081480 A,1991-04-26,US 51858390 A,1990-05-01,3-NAPHTHYL-3-CARBOXYALKYLTHIO OR OXY SUBSTITUTED ALKANOIC ACID LEUKOTRIENE ANTAGONISTS,2081480 9117149 PCTABS00008 This invention relates to alkanoic acid compounds having a naphthyl ring and thio substituents which are useful as leukotriene antagonists.,SMITHKLINE BEECHAM CORP,FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F;;UZINSKAS IRENE N,,https://lens.org/107-232-709-427-478,Patent Application,no,0,0,6,6,0,A61P11/08;;A61P43/00;;C07D257/04;;C07C45/46;;C07C45/56;;C07C45/565;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C323/56,A61K31/16;;A61K31/18;;A61K31/185;;A61K31/19;;A61K31/215;;A61K31/27;;A61K31/275;;A61K31/34;;A61K31/341;;A61K31/415;;A61K31/425;;A61K31/426;;A61P11/08;;A61P43/00;;C07C45/46;;C07C45/56;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C261/04;;C07C317/44;;C07C323/56;;C07D213/00;;C07D233/64;;C07D257/04;;C07D277/22;;C07D277/24;;C07D277/26;;C07D307/38,,0,0,,,,DISCONTINUED
65,CA,A1,CA 3126618 A1,124-843-934-126-857,2020-07-23,2020,CA 3126618 A,2019-08-29,US 201916252026 A;;IB 2019057297 W,2019-01-18,ULTRASONIC GAS METERS AND RELATED FLOWTUBES,"An ultrasonic meter configured to operate in multiple classes is provided including a flowtube having an inlet at a first end and an outlet at a second end, opposite the first end; and first and second face to face transducers, the first transducer being positioned at the first end of the flowtube and the second transducer being positioned at the second end of the flowtube, wherein the first and second face to face transducers are positioned in line with flow through the ultrasonic meter. Related flowtubes are also provided herein.",SENSUS SPECTRUM LLC,HEALY DAVID;;SOKOL BENJAMIN JOHN;;MEANWELL HILARY JANE;;FRAZEE ERIC;;PATERSON CHARLIE,,https://lens.org/124-843-934-126-857,Patent Application,no,0,0,6,6,0,G01F1/662;;G01F1/662;;G01F15/002,G01F1/66,,0,0,,,,PENDING
66,WO,A2,WO 2003/040811 A2,157-880-924-121-921,2003-05-15,2003,US 0235108 W,2002-11-01,US 451801 A,2001-11-02,SYSTEM AND METHOD FOR MINIMIZING IMAGE DEGRADATION IN LCD MICRODISPLAYS,"A system and method for writing a video frame row by row in a liquid crystal display (LCD) having a matrix of liquid crystal pixels arranged in a plurality of columns and a plurality of rows is provided. The system and method are constructed and arranged to minimize image degradation in the LCD by charging the column capacitors to a mid gray voltage or some other common fixed voltage prior to writing each row. The fixed charge voltage may be achieved by coupling all of the column capacitors together and allowing them to equalize to an average voltage before each row is written. In a preferred embodiment, a successive column or group of columns is charged to the mid gray voltage while the preceding column is being charged to the desired video voltage and that sequence is repeated until each pixel in each row is written.",THREE FIVE SYSTEMS INC,KLEIN TERENCE R;;FRAZEE JEROME A;;FLACK RUSSELL J;;WATERMAN JOHN KARL,,https://lens.org/157-880-924-121-921,Patent Application,yes,0,0,5,5,0,G09G3/2011;;G09G3/3648;;G09G3/3688;;G09G2310/0248;;G09G2320/0209;;G09G3/3688;;G09G3/2011;;G09G2310/0248;;G09G3/3648;;G09G2320/0209,G09G3/20;;G09G3/36,,0,0,,,,PENDING
67,EP,A4,EP 0528957 A4,178-647-485-956-409,1993-05-05,1993,EP 91910099 A,1991-04-26,US 51712090 A,1990-05-01,FIVE-MEMBERED RING ALKANOIC ACID LEUKOTRIENE ANTAGONISTS,,SMITH-KLINE BEECHAM CORPORATION,"FRAZEE, JAMES, SIMPSON;;GLEASON, JOHN, GERALD;;HALL, RALPH, FLOYD;;UZINSKAS, IRENE, NIJOLE",,https://lens.org/178-647-485-956-409,Search Report,no,0,0,6,6,0,A61K31/38;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/64;;C07D307/54;;C07D333/24;;C07D403/06;;C07D409/06,A61K31/34;;A61K31/341;;A61K31/38;;A61K31/381;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/54;;C07D233/64;;C07D233/70;;C07D233/84;;C07D257/02;;C07D257/04;;C07D307/42;;C07D307/54;;C07D333/16;;C07D333/18;;C07D333/24;;C07D403/06;;C07D409/06;;C07D413/04,,2,0,,,No further relevant documents disclosed;;See also references of WO 9116889A1,DISCONTINUED
68,EP,A1,EP 0536310 A1,003-732-950-535-301,1993-04-14,1993,EP 91913413 A,1991-06-14,US 54525890 A,1990-06-28,CHEMICAL COMPOUNDS.,Inhibiteurs de leucotriènes composés d'acides proprioniques à substitution acide phényl/thioalcanoïque à substitution quinolinyle de la formule générale (I) dont on décrit les substituants.,SMITHKLINE BEECHAM CORP,COUSINS RUSSELL DONOVAN;;FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/003-732-950-535-301,Patent Application,yes,0,0,10,10,0,A61P11/00;;A61P43/00;;C07D215/14;;C07D401/06;;C07D401/06;;C07D215/12;;C07D215/12;;C07D215/14;;C07D215/14;;C07D215/18;;C07D215/18,A61K31/47;;A61P11/00;;A61P43/00;;C07D215/12;;C07D215/14;;C07D215/18;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,0,0,,,,DISCONTINUED
69,WO,A3,WO 2003/040811 A3,106-692-091-847-331,2003-06-19,2003,US 0235108 W,2002-11-01,US 451801 A,2001-11-02,SYSTEM AND METHOD FOR MINIMIZING IMAGE DEGRADATION IN LCD MICRODISPLAYS,"A system and method for writing a video frame row by row in a liquid crystal display (LCD) having a matrix of liquid crystal pixels arranged in a plurality of columns and a plurality of rows is provided. The system and method are constructed and arranged to minimize image degradation in the LCD by charging the column capacitors to a mid gray voltage or some other common fixed voltage prior to writing each row. The fixed charge voltage may be achieved by coupling all of the column capacitors together and allowing them to equalize to an average voltage before each row is written. In a preferred embodiment, a successive column or group of columns is charged to the mid gray voltage while the preceding column is being charged to the desired video voltage and that sequence is repeated until each pixel in each row is written.",THREE FIVE SYSTEMS INC,KLEIN TERENCE R;;FRAZEE JEROME A;;FLACK RUSSELL J;;WATERMAN JOHN KARL,,https://lens.org/106-692-091-847-331,Search Report,yes,5,0,5,5,0,G09G3/2011;;G09G3/3648;;G09G3/3688;;G09G2310/0248;;G09G2320/0209;;G09G3/3688;;G09G3/2011;;G09G2310/0248;;G09G3/3648;;G09G2320/0209,G09G3/20;;G09G3/36,,0,0,,,,PENDING
70,US,A1,US 2020/0232828 A1,110-811-649-649-224,2020-07-23,2020,US 201916252026 A,2019-01-18,US 201916252026 A,2019-01-18,Dual Class Ultrasonic Gas Meters and Related Flowtubes,"An ultrasonic meter configured to operate in multiple classes is provided including a flowtube having an inlet at a first end and an outlet at a second end, opposite the first end; and first and second face to face transducers, the first transducer being positioned at the first end of the flowtube and the second transducer being positioned at the second end of the flowtube, wherein the first and second face to face transducers are positioned in line with flow through the ultrasonic meter. Related flowtubes are also provided herein.",SENSUS SPECTRUM LLC,HEALY DAVID;;SOKOL BENJAMIN JOHN;;MEANWELL HILARY JANE;;FRAZEE ERIC;;PATERSON CHARLIE,SENSUS SPECTRUM LLC (2019-02-25),https://lens.org/110-811-649-649-224,Patent Application,yes,5,0,6,6,0,G01F1/662;;G01F1/662;;G01F15/002,G01F1/66;;G01F15/00,,0,0,,,,ACTIVE
71,US,B2,US 10866127 B2,002-126-521-887-10X,2020-12-15,2020,US 201916252026 A,2019-01-18,US 201916252026 A,2019-01-18,Dual class ultrasonic gas meters and related flowtubes,"An ultrasonic meter configured to operate in multiple classes is provided including a flowtube having an inlet at a first end and an outlet at a second end, opposite the first end; and first and second face to face transducers, the first transducer being positioned at the first end of the flowtube and the second transducer being positioned at the second end of the flowtube, wherein the first and second face to face transducers are positioned in line with flow through the ultrasonic meter. Related flowtubes are also provided herein.",SENSUS SPECTRUM LLC,HEALY DAVID;;SOKOL BENJAMIN JOHN;;MEANWELL HILARY JANE;;FRAZEE ERIC;;PATERSON CHARLIE,SENSUS SPECTRUM LLC (2019-02-25),https://lens.org/002-126-521-887-10X,Granted Patent,yes,18,0,6,6,0,G01F1/662;;G01F1/662;;G01F15/002,G01F1/66;;G01F15/00,,1,0,,,"Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, PCT/IB2019/057297, dated Dec. 29, 2019, 15 pages.",ACTIVE
72,US,B2,US 7245122 B2,018-398-161-519-521,2007-07-17,2007,US 31592405 A,2005-12-21,US 31592405 A,2005-12-21,Vane actuated magnetic drive mode sensor,"A vane actuated drive mode sensor is generally composed of two primary components, including a drive mode sensor array and an actuator. The sensor array can be provided as a housing composed of a plurality of Hall Effect (HE) sensors, magnets and the electronics associated with the sensors. The actuator, also referred to as a vane, can be provided as a plate constructed from a magnetic material, such as, for example, ferrous steel, and can be provided with holes punched thereon at different places depending on the requirement of a user. The actuator can be connected to a user's driver and can slide on and/or within the housing.",HONEYWELL INT INC,ALFORS EUGENE D;;EICHHOLZ KENNETH L;;FRAZEE LAWRENCE E;;PATIN JOHN S,HONEYWELL INTERNATIONAL INC (2005-12-16),https://lens.org/018-398-161-519-521,Granted Patent,yes,11,0,4,4,0,F16H59/105;;F16H59/105;;G01D5/147;;G01D5/147;;G01D2205/80,G01B7/14;;G01R33/07,324/207.2;;324/251;;324/207.24,1,0,,,"Sensors, Tyco Electronics, Catalog 1773105, pp. 19-1-19-10.",INACTIVE
73,CA,A1,CA 2083710 A1,072-837-055-010-289,1991-12-29,1991,CA 2083710 A,1991-06-14,US 54525890 A,1990-06-28,QUINOLINYL SUBSTITUTED PHENYL/THIOALKANOIC ACID SUBSTITUTED PROPIONIC ACIDS,"2083710 9200279 PCTABS00010 This invention covers quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids leukotriene inhibitors having general formula (I), where the substituents are defined herein.",SMITHKLINE BEECHAM CORP,COUSINS RUSSELL D;;FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F,,https://lens.org/072-837-055-010-289,Patent Application,no,0,0,10,10,0,A61P11/00;;A61P43/00;;C07D215/14;;C07D401/06;;C07D401/06;;C07D215/12;;C07D215/12;;C07D215/14;;C07D215/14;;C07D215/18;;C07D215/18,A61K31/47;;A61P11/00;;A61P43/00;;C07D215/12;;C07D215/14;;C07D215/18;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,0,0,,,,DISCONTINUED
74,EP,A4,EP 0527175 A4,089-759-304-976-532,1993-05-05,1993,EP 91908637 A,1991-04-26,US 51858390 A,1990-05-01,3-NAPHTHYL-3-CARBOXYALKYLTHIO OR OXY SUBSTITUTED ALKANOIC ACID LEUKOTRIENE ANTAGONISTS,,SMITHKLINE BEECHAM CORPORATION,"FRAZEE, JAMES, SIMPSON;;GLEASON, JOHN, GERALD;;HALL, RALPH, FLOYD;;UZINSKAS, IRENE, NIJOLE",,https://lens.org/089-759-304-976-532,Search Report,no,2,0,6,6,0,A61P11/08;;A61P43/00;;C07D257/04;;C07C45/46;;C07C45/56;;C07C45/565;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C323/56,A61K31/16;;A61K31/18;;A61K31/185;;A61K31/19;;A61K31/215;;A61K31/27;;A61K31/275;;A61K31/34;;A61K31/341;;A61K31/415;;A61K31/425;;A61K31/426;;A61P11/08;;A61P43/00;;C07C45/46;;C07C45/56;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C261/04;;C07C317/44;;C07C323/56;;C07D213/00;;C07D233/64;;C07D257/04;;C07D277/22;;C07D277/24;;C07D277/26;;C07D307/38,,2,1,084-208-214-788-981,10.1021/jm00389a001;;3035179,"JOURNAL OF MEDICINAL CHEMISTRY vol. 30, no. 6, June 1987, WASHINGTON US pages 959 - 961 J.G. GLEASON ET AL. 'High Affinity Leukotriene Receptor Antagonists. Synthesis and Pharmalogical Characterization of 2-Hydroxy-3-Ä(2-carbox yethyl)thioÜ-3-[2-(8-phenyloctyl)phenyl]pr opanoic Acid.';;See also references of WO 9117149A1",DISCONTINUED
75,WO,A1,WO 1991/016889 A1,004-620-772-442-11X,1991-11-14,1991,US 9102884 W,1991-04-26,US 51712090 A,1990-05-01,FIVE-MEMBERED RING ALKANOIC ACID LEUKOTRIENE ANTAGONISTS,This invention relates to alkanoic acid compounds having a 5-membered heterocyclic ring and a thio substituent which are useful as leukotriene antagonists.,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;UZINSKAS IRENE NIJOLE,,https://lens.org/004-620-772-442-11X,Patent Application,yes,5,3,6,6,0,A61K31/38;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/64;;C07D307/54;;C07D333/24;;C07D403/06;;C07D409/06,A61K31/34;;A61K31/341;;A61K31/38;;A61K31/381;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/54;;C07D233/64;;C07D233/70;;C07D233/84;;C07D257/02;;C07D257/04;;C07D307/42;;C07D307/54;;C07D333/16;;C07D333/18;;C07D333/24;;C07D403/06;;C07D409/06;;C07D413/04,,1,0,,,See also references of EP 0528957A4,PENDING
76,TW,A,TW 200302446 A,078-193-596-802-630,2003-08-01,2003,TW 91132527 A,2002-11-01,US 451801 A,2001-11-02,System and method for minimizing image degradation in LCD microdisplays,"A system and method for writing a video frame row by row in a liquid crystal display (LCD) having a matrix of liquid crystal pixels arranged in a plurality of columns and a plurality of rows is provided. The system and method are constructed and arranged to minimize image degradation in the LCD by charging the column capacitors to a mid gray voltage or some other common fixed voltage prior to writing each row. The fixed charge voltage may be achieved by coupling all of the column capacitors together and allowing them to equalize to an average voltage before each row is written. In a referred embodiment, a successive column or group of columns is charged to the mid gray voltage while the preceding column is being charged to the desired video voltage and that sequence is repeated until each pixel in each row is written.",THREE FIVE SYSTEMS INC,KLEIN TERENCE R;;FRAZEE JEROME A;;FLACK RUSSELL J;;WATERMAN JOHN KARL,,https://lens.org/078-193-596-802-630,Patent of Addition,no,0,0,5,5,0,G09G3/2011;;G09G3/3648;;G09G3/3688;;G09G2310/0248;;G09G2320/0209;;G09G3/3688;;G09G3/2011;;G09G2310/0248;;G09G3/3648;;G09G2320/0209,G09G3/20;;G09G3/36,,0,0,,,,PENDING
77,AU,A,AU 1991/079029 A,120-481-448-604-357,1991-11-27,1991,AU 1991/079029 A,1991-04-26,US 51712090 A,1990-05-01,FIVE-MEMBERED RING ALKANOIC ACID LEUKOTRIENE ANTAGONISTS,,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;UZINSKAS IRENE NIJOLE,,https://lens.org/120-481-448-604-357,Patent Application,no,0,0,6,6,0,A61K31/38;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/64;;C07D307/54;;C07D333/24;;C07D403/06;;C07D409/06,A61K31/34;;A61K31/341;;A61K31/38;;A61K31/381;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/54;;C07D233/64;;C07D233/70;;C07D233/84;;C07D257/02;;C07D257/04;;C07D307/42;;C07D307/54;;C07D333/16;;C07D333/18;;C07D333/24;;C07D403/06;;C07D409/06;;C07D413/04,,0,0,,,,PENDING
78,US,A1,US 2003/0085856 A1,128-392-033-366-453,2003-05-08,2003,US 451801 A,2001-11-02,US 451801 A,2001-11-02,System and method for minimizing image degradation in LCD microdisplays,"
   A system and method for writing a video frame row by row in a liquid crystal display (LCD) having a matrix of liquid crystal pixels arranged in a plurality of columns and a plurality of rows is provided. The system and method are constructed and arranged to minimize image degradation in the LCD by charging the column capacitors to a mid gray voltage or some other common fixed voltage prior to writing each row. The fixed charge voltage may be achieved by coupling all of the column capacitors together and allowing them to equalize to an average voltage before each row is written. In a preferred embodiment, a successive column or group of columns is charged to the mid gray voltage while the preceding column is being charged to the desired video voltage and that sequence is repeated until each pixel in each row is written. 
",KLEIN TERENCE R;;FRAZEE JEROME A;;FLACK RUSSELL J;;WATERMAN JOHN KARL,KLEIN TERENCE R;;FRAZEE JEROME A;;FLACK RUSSELL J;;WATERMAN JOHN KARL,THREE-FIVE SYSTEMS INC (2002-01-22);;BRILLIAN CORPORATION (2004-02-23),https://lens.org/128-392-033-366-453,Patent Application,yes,7,2,5,5,0,G09G3/2011;;G09G3/3648;;G09G3/3688;;G09G2310/0248;;G09G2320/0209;;G09G3/3688;;G09G3/2011;;G09G2310/0248;;G09G3/3648;;G09G2320/0209,G09G3/20;;G09G3/36,345/87,0,0,,,,DISCONTINUED
79,AU,A1,AU 2002/342273 A1,060-006-477-786-594,2003-05-19,2003,AU 2002/342273 A,2002-11-01,US 451801 A;;US 0235108 W,2001-11-02,System and method for minimizing image degradation in lcd microdisplays,,THREE FIVE SYSTEMS INC,FRAZEE JEROME A;;WATERMAN JOHN KARL;;KLEIN TERENCE R;;FLACK RUSSELL J,,https://lens.org/060-006-477-786-594,Patent Application,no,0,0,5,5,0,G09G3/2011;;G09G3/3648;;G09G3/3688;;G09G2310/0248;;G09G2320/0209;;G09G3/3688;;G09G3/2011;;G09G2310/0248;;G09G3/3648;;G09G2320/0209,G09G3/20;;G09G3/36,,0,0,,,,DISCONTINUED
80,AU,A,AU 1991/082388 A,059-790-355-642-572,1992-01-23,1992,AU 1991/082388 A,1991-06-14,US 54525890 A,1990-06-28,CHEMICAL COMPOUNDS,,SMITHKLINE BEECHAM CORP,COUSINS RUSSELL DONOVAN;;FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD,,https://lens.org/059-790-355-642-572,Patent Application,no,0,0,10,10,0,A61P11/00;;A61P43/00;;C07D215/14;;C07D401/06;;C07D401/06;;C07D215/12;;C07D215/12;;C07D215/14;;C07D215/14;;C07D215/18;;C07D215/18,A61K31/47;;A61P11/00;;A61P43/00;;C07D215/12;;C07D215/14;;C07D215/18;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,0,0,,,,PENDING
81,EP,A1,EP 0528957 A1,099-056-210-342-178,1993-03-03,1993,EP 91910099 A,1991-04-26,US 51712090 A,1990-05-01,FIVE-MEMBERED RING ALKANOIC ACID LEUKOTRIENE ANTAGONISTS.,"Composés d'acide alcanoïque possédant un anneau hétérocyclique à cinq membres et un substituant thio, et utiles en tant qu'antagonistes de leucotriène.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;UZINSKAS IRENE NIJOLE,,https://lens.org/099-056-210-342-178,Patent Application,yes,0,0,6,6,0,A61K31/38;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/64;;C07D307/54;;C07D333/24;;C07D403/06;;C07D409/06,A61K31/34;;A61K31/341;;A61K31/38;;A61K31/381;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/54;;C07D233/64;;C07D233/70;;C07D233/84;;C07D257/02;;C07D257/04;;C07D307/42;;C07D307/54;;C07D333/16;;C07D333/18;;C07D333/24;;C07D403/06;;C07D409/06;;C07D413/04,,0,0,,,,DISCONTINUED
82,CA,A1,CA 2081462 A1,008-493-001-168-593,1991-11-02,1991,CA 2081462 A,1991-04-26,US 51712090 A;;US 9102884 W,1990-05-01,FIVE-MEMBERED RING ALKANOIC ACID LEUKOTRIENE ANTAGONISTS,2081462 9116889 PCTABS00008 This invention relates to alkanoic acid compounds having a 5-membered heterocyclic ring and a thio substituent which are useful as leukotriene antagonists.,,FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F;;UZINSKAS IRENE N,,https://lens.org/008-493-001-168-593,Patent Application,no,0,0,6,6,0,A61K31/38;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/64;;C07D307/54;;C07D333/24;;C07D403/06;;C07D409/06,A61K31/34;;A61K31/341;;A61K31/38;;A61K31/381;;A61K31/415;;A61P9/08;;A61P9/10;;A61P37/08;;A61P43/00;;C07D233/54;;C07D233/64;;C07D233/70;;C07D233/84;;C07D257/02;;C07D257/04;;C07D307/42;;C07D307/54;;C07D333/16;;C07D333/18;;C07D333/24;;C07D403/06;;C07D409/06;;C07D413/04,,0,0,,,,DISCONTINUED
83,WO,A2,WO 2007/075511 A2,199-174-547-132-443,2007-07-05,2007,US 2006/0048131 W,2006-12-15,US 31592405 A,2005-12-21,VANE ACTUATED MAGNETIC DRIVE MODE SENSOR,"A vane actuated drive mode sensor is generally composed of two primary components, including a drive mode sensor array and an actuator. The sensor array can be provided as a housing composed of a plurality of Hall Effect (HE) sensors magnets and the electronics associated with the sensors. The actuator, also referred to as a vane, can be provided as a plate constructed from a magnetic material, such as for example, ferrous steel, and can be provided with holes punched thereon at differen places depending on the requirement of a user. The actuator can be connected to user's driver and can slide on and/or within the housing.",HONEYWELL INT INC;;ALFORS EUGENE D;;ELCHHOLZ KENNETH L;;FRAZEE LAWRENCE E;;PATIN JOHN S,ALFORS EUGENE D;;ELCHHOLZ KENNETH L;;FRAZEE LAWRENCE E;;PATIN JOHN S,,https://lens.org/199-174-547-132-443,Patent Application,yes,0,1,4,4,0,F16H59/105;;F16H59/105;;G01D5/147;;G01D5/147;;G01D2205/80,,,0,0,,,,PENDING
84,AU,A,AU 1991/077694 A,169-166-266-235-245,1991-11-27,1991,AU 1991/077694 A,1991-04-26,US 51858390 A,1990-05-01,3-NAPHTHYL-3-CARBOXYALKYLTHIO OR OXY SUBSTITUTED ALKANOIC ACID LEUKOTRIENE ANTAGONISTS,,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;UZINSKAS IRENE NIJOLE,,https://lens.org/169-166-266-235-245,Patent Application,no,0,0,6,6,0,A61P11/08;;A61P43/00;;C07D257/04;;C07C45/46;;C07C45/56;;C07C45/565;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C323/56,A61K31/16;;A61K31/18;;A61K31/185;;A61K31/19;;A61K31/215;;A61K31/27;;A61K31/275;;A61K31/34;;A61K31/341;;A61K31/415;;A61K31/425;;A61K31/426;;A61P11/08;;A61P43/00;;C07C45/46;;C07C45/56;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C261/04;;C07C317/44;;C07C323/56;;C07D213/00;;C07D233/64;;C07D257/04;;C07D277/22;;C07D277/24;;C07D277/26;;C07D307/38,,0,0,,,,PENDING
85,EP,A1,EP 0527175 A1,017-776-438-188-788,1993-02-17,1993,EP 91908637 A,1991-04-26,US 51858390 A,1990-05-01,3-NAPHTHYL-3-CARBOXYALKYLTHIO OR OXY SUBSTITUTED ALKANOIC ACID LEUKOTRIENE ANTAGONISTS.,Composés d'acide alcanoïque possédant un anneau naphtyle et des substituants thio utiles en tant qu'antagonistes de leucotriène.,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;UZINSKAS IRENE NIJOLE,,https://lens.org/017-776-438-188-788,Patent Application,yes,0,0,6,6,0,A61P11/08;;A61P43/00;;C07D257/04;;C07C45/46;;C07C45/56;;C07C45/565;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C323/56,A61K31/16;;A61K31/18;;A61K31/185;;A61K31/19;;A61K31/215;;A61K31/27;;A61K31/275;;A61K31/34;;A61K31/341;;A61K31/415;;A61K31/425;;A61K31/426;;A61P11/08;;A61P43/00;;C07C45/46;;C07C45/56;;C07C45/68;;C07C45/71;;C07C59/66;;C07C59/68;;C07C69/76;;C07C69/94;;C07C261/04;;C07C317/44;;C07C323/56;;C07D213/00;;C07D233/64;;C07D257/04;;C07D277/22;;C07D277/24;;C07D277/26;;C07D307/38,,0,0,,,,DISCONTINUED
86,WO,A1,WO 2020/148578 A1,066-007-536-446-892,2020-07-23,2020,IB 2019057297 W,2019-08-29,US 201916252026 A,2019-01-18,ULTRASONIC GAS METERS AND RELATED FLOWTUBES,"An ultrasonic meter configured to operate in multiple classes is provided including a flowtube having an inlet at a first end and an outlet at a second end, opposite the first end; and first and second face to face transducers, the first transducer being positioned at the first end of the flowtube and the second transducer being positioned at the second end of the flowtube, wherein the first and second face to face transducers are positioned in line with flow through the ultrasonic meter. Related flowtubes are also provided herein.",SENSUS SPECTRUM LLC,HEALY DAVID;;SOKOL BENJAMIN JOHN;;MEANWELL HILARY JANE;;FRAZEE ERIC;;PATERSON CHARLIE,,https://lens.org/066-007-536-446-892,Patent Application,yes,6,0,6,6,0,G01F1/662;;G01F1/662;;G01F15/002,G01F1/66,,0,0,,,,PENDING
87,WO,A3,WO 2007/075511 A3,126-970-711-406-389,2007-08-16,2007,US 2006/0048131 W,2006-12-15,US 31592405 A,2005-12-21,VANE ACTUATED MAGNETIC DRIVE MODE SENSOR,"A vane actuated drive mode sensor is generally composed of two primary components, including a drive mode sensor array and an actuator. The sensor array can be provided as a housing composed of a plurality of Hall Effect (HE) sensors magnets and the electronics associated with the sensors. The actuator, also referred to as a vane, can be provided as a plate constructed from a magnetic material, such as for example, ferrous steel, and can be provided with holes punched thereon at differen places depending on the requirement of a user. The actuator can be connected to user's driver and can slide on and/or within the housing.",HONEYWELL INT INC;;ALFORS EUGENE D;;ELCHHOLZ KENNETH L;;FRAZEE LAWRENCE E;;PATIN JOHN S,ALFORS EUGENE D;;ELCHHOLZ KENNETH L;;FRAZEE LAWRENCE E;;PATIN JOHN S,,https://lens.org/126-970-711-406-389,Search Report,yes,8,0,4,4,0,F16H59/105;;F16H59/105;;G01D5/147;;G01D5/147;;G01D2205/80,G01D5/14;;F16H25/20,,0,0,,,,PENDING
88,US,A1,US 2007/0139038 A1,182-167-967-212-797,2007-06-21,2007,US 31592405 A,2005-12-21,US 31592405 A,2005-12-21,Vane actuated magnetic drive mode sensor,"A vane actuated drive mode sensor is generally composed of two primary components, including a drive mode sensor array and an actuator. The sensor array can be provided as a housing composed of a plurality of Hall Effect (HE) sensors, magnets and the electronics associated with the sensors. The actuator, also referred to as a vane, can be provided as a plate constructed from a magnetic material, such as, for example, ferrous steel, and can be provided with holes punched thereon at different places depending on the requirement of a user. The actuator can be connected to a user's driver and can slide on and/or within the housing.",HONEYWELL INT INC,ALFORS EUGENE D;;EICHHOLZ KENNETH L;;FRAZEE LAWRENCE E;;PATIN JOHN S,HONEYWELL INTERNATIONAL INC (2005-12-16),https://lens.org/182-167-967-212-797,Patent Application,yes,11,2,4,4,0,F16H59/105;;F16H59/105;;G01D5/147;;G01D5/147;;G01D2205/80,G01B7/30,324/207.2,0,0,,,,INACTIVE
89,WO,A3,WO 2001/051096 A3,085-110-888-968-488,2001-12-20,2001,US 0101210 W,2001-01-12,US 17636200 P,2000-01-14,"PATHOGEN-REDUCING SYSTEMS, COMPOSITIONS, ARTICLES AND METHODS EMPLOYING OZONE","The present invention relates to pathogen-reducing systems and methods employing ozone and compositions and articles useful therein. More particularly, the present invention relates to pathogen-reducing systems and methods useful in pathogen-reducing pathogen containing substrates/articles, such as sponges, wash cloths, scouring pads (i.e., plastic, metallic), utensils, dishes, cookware, pots, pans, skillets, baby bottles, baby nipples, glassware, dentures, brushes, gloves, reusable wipes, and the like wherein the substrate/article is treated with an ozone-enhancing composition and subjected with ozone in a closed environment, such that the ozone-enhancing composition and ozone are in contact with the substrate/article to be treated contemporaneously.",PROCTER & GAMBLE,SEVERNS JOHN CORT;;HARTMAN FREDERICK ANTHONY;;THOEN CHRISTIAAN ARTHUR JACQUE;;FRAZEE MICHAEL CHARLES,,https://lens.org/085-110-888-968-488,Search Report,yes,5,0,5,5,0,A61L2/202;;C11D3/3942;;C11D3/48;;C11D17/041;;C11D3/3942;;C11D17/041;;C11D3/48;;A61L2/202,A61L2/20;;C11D3/02;;C11D3/48;;C11D7/02;;C11D17/04,,0,0,,,,PENDING
90,US,A1,US 2001/0041665 A1,045-538-973-013-172,2001-11-15,2001,US 75868101 A,2001-01-11,US 75868101 A;;US 17636200 P,2000-01-14,"Pathogen-reducing systems, compositions, articles and methods employing ozone","
   The present invention relates to pathogen-reducing systems and methods employing ozone and compositions and articles useful therein. More particularly, the present invention relates to pathogen-reducing systems and methods useful in pathogen-reducing pathogen containing substrates/articles, such as sponges, wash cloths, scouring pads (i.e., plastic, metallic), utensils, dishes, cookware, pots, pans, skillets, baby bottles, baby nipples, glassware, dentures, brushes, gloves, reusable wipes, and the like wherein the substrate/article is treated with an ozone-enhancing composition and subjected with ozone in a closed environment, such that the ozone-enhancing composition and ozone are in contact with the substrate/article to be treated contemporaneously. 
",SEVERNS JOHN CORT;;HARTMAN FREDERICK ANTHONY;;KAMIEL THOEN CHRISTIAAN ARTHUR JACQUES;;FRAZEE MICHAEL CHARLES,SEVERNS JOHN CORT;;HARTMAN FREDERICK ANTHONY;;KAMIEL THOEN CHRISTIAAN ARTHUR;;FRAZEE MICHAEL CHARLES,PROCTER & GAMBLE COMPANY THE (2001-03-02),https://lens.org/045-538-973-013-172,Patent Application,yes,0,8,5,5,0,A61L2/202;;C11D3/3942;;C11D3/48;;C11D17/041;;C11D3/3942;;C11D17/041;;C11D3/48;;A61L2/202,A61L2/20;;C11D3/02;;C11D3/48;;C11D7/02;;C11D17/04,510/218;;510/505,0,0,,,,DISCONTINUED
91,WO,A2,WO 2001/051096 A2,103-169-480-676-796,2001-07-19,2001,US 0101210 W,2001-01-12,US 17636200 P,2000-01-14,"PATHOGEN-REDUCING SYSTEMS, COMPOSITIONS, ARTICLES AND METHODS EMPLOYING OZONE","The present invention relates to pathogen-reducing systems and methods employing ozone and compositions and articles useful therein. More particularly, the present invention relates to pathogen-reducing systems and methods useful in pathogen-reducing pathogen containing substrates/articles, such as sponges, wash cloths, scouring pads (i.e., plastic, metallic), utensils, dishes, cookware, pots, pans, skillets, baby bottles, baby nipples, glassware, dentures, brushes, gloves, reusable wipes, and the like wherein the substrate/article is treated with an ozone-enhancing composition and subjected with ozone in a closed environment, such that the ozone-enhancing composition and ozone are in contact with the substrate/article to be treated contemporaneously.",PROCTER & GAMBLE,SEVERNS JOHN CORT;;HARTMAN FREDERICK ANTHONY;;THOEN CHRISTIAAN ARTHUR JACQUE;;FRAZEE MICHAEL CHARLES,,https://lens.org/103-169-480-676-796,Patent Application,yes,0,8,5,5,0,A61L2/202;;C11D3/3942;;C11D3/48;;C11D17/041;;C11D3/3942;;C11D17/041;;C11D3/48;;A61L2/202,A61L2/20;;C11D3/02;;C11D3/48;;C11D7/02;;C11D17/04,,0,0,,,,PENDING
92,AU,A,AU 2001/029463 A,008-064-275-987-646,2001-07-24,2001,AU 2001/029463 A,2001-01-12,US 17636200 P;;US 0101210 W,2000-01-14,"Pathogen-reducing systems, compositions, articles and methods employing ozone",,PROCTER & GAMBLE,SEVERNS JOHN CORT;;HARTMAN FREDERICK ANTHONY;;THOEN CHRISTIAAN ARTHUR JACQUE;;FRAZEE MICHAEL CHARLES,,https://lens.org/008-064-275-987-646,Patent Application,no,0,0,5,5,0,A61L2/202;;C11D3/3942;;C11D3/48;;C11D17/041;;C11D3/3942;;C11D17/041;;C11D3/48;;A61L2/202,A61L2/20;;C11D3/02;;C11D3/48;;C11D7/02;;C11D17/04,,0,0,,,,PENDING
93,ZA,B,ZA 917261 B,161-301-147-870-623,1992-09-30,1992,ZA 917261 A,1991-09-12,US 58195890 A,1990-09-13,PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS,,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;JAMES SIMPSON FRAZEE;;HALL RALPH FLOYD;;RALPH FLOYD HALL;;UZINSKAS IRENE NIJOLE;;IRENE NIJOLE UZINSKAS;;GLEASON JOHN GERALD;;JOHN GERALD GLEASON;;KINZIG CHARLES MICHAEL;;CHARLES MICHAEL KINZIG,,https://lens.org/161-301-147-870-623,Granted Patent,no,0,0,10,10,0,A61P29/00;;A61P43/00;;C07D213/70;;C07D213/70;;C07D213/55,A61K31/44;;A61K31/4418;;A61P29/00;;A61P43/00;;C07D213/55;;C07D213/70,,0,0,,,,EXPIRED
94,WO,A1,WO 2007/067422 A1,046-721-031-198-478,2007-06-14,2007,US 2006/0045962 W,2006-11-30,US 29537105 A,2005-12-05,CHIP ON LEAD FRAME FOR SMALL PACKAGE SPEED SENSOR,"A sensor package apparatus includes a lead frame substrate that supports one or more electrical components, which are connected to and located on the lead frame substrate. A plurality of wire bonds are also provided, which electrically connect the electrical components to the lead frame substrate, wherein the lead frame substrate is encapsulated by a thermoset plastic to protect the plurality of wire bonds and at least one electrical component, thereby providing a sensor package apparatus comprising the lead frame substrate, the electrical component(s), and the wire bonds, while eliminating a need for a Printed Circuit Board (PCB) or a ceramic substrate in place of the lead frame substrate as a part of the sensor package apparatus. A conductive epoxy can also be provided for maintaining a connection of the electrical component(s) to the lead frame substrate. The electrical components can constitute, for example, an IC chip and/or a sensing element (e.g., a magnetoresistive component) or sense die.",HONEYWELL INT INC;;FRAZEE LAWRENCE E;;LAMB WAYNE A;;PATIN JOHN S;;SCHELONKA PETER A;;STOLFUS JOEL D,FRAZEE LAWRENCE E;;LAMB WAYNE A;;PATIN JOHN S;;SCHELONKA PETER A;;STOLFUS JOEL D,,https://lens.org/046-721-031-198-478,Patent Application,yes,5,2,8,8,0,G01D11/245;;H01L23/49575;;H01L2224/48091;;H01L2224/49171;;H01L23/495;;G01P3/42;;G01D11/24;;H01L23/49575;;G01D11/245;;H01L2224/49171;;H01L2224/48091,H01L23/495;;G01D11/24,,1,0,,,See also references of EP 1958256A1,PENDING
95,US,A1,US 2007/0126088 A1,057-174-810-541-772,2007-06-07,2007,US 29537105 A,2005-12-05,US 29537105 A,2005-12-05,Chip on lead frame for small package speed sensor,"A sensor package apparatus includes a lead frame substrate that supports one or more electrical components, which are connected to and located on the lead frame substrate. A plurality of wire bonds are also provided, which electrically connect the electrical components to the lead frame substrate, wherein the lead frame substrate is encapsulated by a thermoset plastic to protect the plurality of wire bonds and at least one electrical component, thereby providing a sensor package apparatus comprising the lead frame substrate, the electrical component(s), and the wire bonds, while eliminating a need for a Printed Circuit Board (PCB) or a ceramic substrate in place of the lead frame substrate as a part of the sensor package apparatus. A conductive epoxy can also be provided for maintaining a connection of the electrical component(s) to the lead frame substrate. The electrical components can constitute, for example, an IC chip and/or a sensing element (e.g., a magnetoresistive component) or sense die.",HONEYWELL INT INC,FRAZEE LAWRENCE E;;LAMB WAYNE A;;PATIN JOHN S;;SCHELONKA PETER A;;STOLFUS JOEL D,HONEYWELL INTERNATIONAL INC (2005-12-01);;SENSATA TECHNOLOGIES INC (2011-01-28),https://lens.org/057-174-810-541-772,Patent Application,yes,18,22,8,8,0,G01D11/245;;H01L23/49575;;H01L2224/48091;;H01L2224/49171;;H01L23/495;;G01P3/42;;G01D11/24;;H01L23/49575;;G01D11/245;;H01L2224/49171;;H01L2224/48091,H01L23/495,257/666,0,0,,,,INACTIVE
96,US,B2,US 7378721 B2,070-228-081-696-185,2008-05-27,2008,US 29537105 A,2005-12-05,US 29537105 A,2005-12-05,Chip on lead frame for small package speed sensor,"A sensor package apparatus includes a lead frame substrate that supports one or more electrical components, which are connected to and located on the lead frame substrate. A plurality of wire bonds are also provided, which electrically connect the electrical components to the lead frame substrate, wherein the lead frame substrate is encapsulated by a thermoset plastic to protect the plurality of wire bonds and at least one electrical component, thereby providing a sensor package apparatus comprising the lead frame substrate, the electrical component(s), and the wire bonds, while eliminating a need for a Printed Circuit Board (PCB) or a ceramic substrate in place of the lead frame substrate as a part of the sensor package apparatus. A conductive epoxy can also be provided for maintaining a connection of the electrical component(s) to the lead frame substrate. The electrical components can constitute, for example, an IC chip and/or a sensing element (e.g., a magnetoresistive component) or sense die.",HONEYWELL INT INC,FRAZEE LAWRENCE E;;LAMB WAYNE A;;PATIN JOHN S;;SCHELONKA PETER A;;STOLFUS JOEL D,HONEYWELL INTERNATIONAL INC (2005-12-01);;SENSATA TECHNOLOGIES INC (2011-01-28),https://lens.org/070-228-081-696-185,Granted Patent,yes,21,27,8,8,0,G01D11/245;;H01L23/49575;;H01L2224/48091;;H01L2224/49171;;H01L23/495;;G01P3/42;;G01D11/24;;H01L23/49575;;G01D11/245;;H01L2224/49171;;H01L2224/48091,H01L23/495;;G01P3/42,257/666;;257/670;;257/678;;257/787;;257/793;;X257E23001;;X257E23007;;X257E23015;;324/160;;324/161;;324/162;;324/163;;324/164;;324/165,0,0,,,,INACTIVE
97,EP,A1,EP 1958256 A1,040-142-546-153-047,2008-08-20,2008,EP 06838757 A,2006-11-30,US 2006/0045962 W;;US 29537105 A,2005-12-05,CHIP ON LEAD FRAME FOR SMALL PACKAGE SPEED SENSOR,,HONEYWELL INT INC,FRAZEE LAWRENCE E;;LAMB WAYNE A;;PATIN JOHN S;;SCHELONKA PETER A;;STOLFUS JOEL D,"SENSATA TECHNOLOGIES, INC. (2011-06-08)",https://lens.org/040-142-546-153-047,Patent Application,yes,4,0,8,8,0,G01D11/245;;H01L23/49575;;H01L2224/48091;;H01L2224/49171;;H01L23/495;;G01P3/42;;G01D11/24;;H01L23/49575;;G01D11/245;;H01L2224/49171;;H01L2224/48091,H01L23/495;;G01D11/24,,1,0,,,See also references of WO 2007067422A1,DISCONTINUED
98,AU,A,AU 1991/089003 A,126-209-963-776-191,1992-04-15,1992,AU 1991/089003 A,1991-09-10,US 58195890 A,1990-09-13,PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS,,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;UZINSKAS IRENE NIJOLE;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;KINZIG CHARLES MICHAEL,,https://lens.org/126-209-963-776-191,Patent Application,no,0,1,10,10,0,A61P29/00;;A61P43/00;;C07D213/70;;C07D213/70;;C07D213/55,A61K31/44;;A61K31/4418;;A61P29/00;;A61P43/00;;C07D213/55;;C07D213/70,,0,0,,,,PENDING
99,CN,B,CN 101366117 B,165-424-491-354-236,2012-11-07,2012,CN 200680052323 A,2006-11-30,US 2006/0045962 W;;US 29537105 A,2005-12-05,Method for placing chip on lead frame for small package speed sensor,"A sensor package apparatus includes a lead frame substrate that supports one or more electrical components, which are connected to and located on the lead frame substrate. A plurality of wire bonds are also provided, which electrically connect the electrical components to the lead frame substrate, wherein the lead frame substrate is encapsulated by a thermoset plastic to protect the plurality of wire bonds and at least one electrical component, thereby providing a sensor package apparatus comprising the lead frame substrate, the electrical component(s), and the wire bonds, while eliminating aneed for a Printed Circuit Board (PCB) or a ceramic substrate in place of the lead frame substrate as a part of the sensor package apparatus. A conductive epoxy can also be provided for maintaining aconnection of the electrical component(s) to the lead frame substrate. The electrical components can constitute, for example, an IC chip and/or a sensing element (e.g., a magnetoresistive component) or sense die.",SENSATA TECHNOLOGIES INC,PATIN JOHN S;;FRAZEE LAWRENCE E;;SCHELONKA PETER A;;LAMB WAYNE A;;STOLFUS JOEL D,SENSATA TECHNOLOGIES INC. (2011-09-14),https://lens.org/165-424-491-354-236,Granted Patent,no,0,0,8,8,0,G01D11/245;;H01L23/49575;;H01L2224/48091;;H01L2224/49171;;H01L23/495;;G01P3/42;;G01D11/24;;H01L23/49575;;G01D11/245;;H01L2224/49171;;H01L2224/48091,H01L23/495;;G01D11/24,,0,0,,,,INACTIVE
100,MX,A,MX 9101098 A,181-377-766-587-938,1992-05-04,1992,MX 9101098 A,1991-09-13,US 58195890 A,1990-09-13,ACIDOS PIRIDILTIO O PIRIDILOXI-ALCANOICOS,,SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;KINZING CHARLES MICHAEL;;UZINSKAS IRENE NIJOLE,,https://lens.org/181-377-766-587-938,Patent Application,no,0,0,10,10,0,A61P29/00;;A61P43/00;;C07D213/70;;C07D213/70;;C07D213/55,A61K31/44;;A61K31/4418;;A61P29/00;;A61P43/00;;C07D213/55;;C07D213/70,,0,0,,,,PENDING
101,EP,A1,EP 0548291 A1,040-414-646-996-523,1993-06-30,1993,EP 91919733 A,1991-09-10,US 58195890 A,1990-09-13,PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS.,"L'invention concerne des composés d'acides alcanoïques présentant des substituants pyridyl et arylthio ou alkylthio, ou leurs analogues d'oxygène, utiles en tant qu'antogonistes de leucotriènes.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;KINZIG CHARLES MICHAEL;;UZINSKAS IRENE NIJOLE,,https://lens.org/040-414-646-996-523,Patent Application,yes,0,0,10,10,0,A61P29/00;;A61P43/00;;C07D213/70;;C07D213/70;;C07D213/55,A61K31/44;;A61K31/4418;;A61P29/00;;A61P43/00;;C07D213/55;;C07D213/70,,1,0,,,See references of WO 9205156A1,DISCONTINUED
102,CA,A1,CA 2089728 A1,100-348-997-263-497,1992-03-14,1992,CA 2089728 A,1991-09-10,US 58195890 A,1990-09-13,PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS,"2089728 9205156 PCTABS00011 This invention relates to alkanoic acid compounds having pyridyl and arylthio or alkylthio substituents, or their oxygen analogs, which are useful as leukotriene antagonists.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES S;;GLEASON JOHN G;;HALL RALPH F;;KINZIG CHARLES M;;UZINSKAS IRENE N,,https://lens.org/100-348-997-263-497,Patent Application,no,0,0,10,10,0,A61P29/00;;A61P43/00;;C07D213/70;;C07D213/70;;C07D213/55,A61K31/44;;A61K31/4418;;A61P29/00;;A61P43/00;;C07D213/55;;C07D213/70,,0,0,,,,DISCONTINUED
103,KR,A,KR 20080075549 A,121-721-080-921-384,2008-08-18,2008,KR 20087016413 A,2008-07-04,US 29537105 A,2005-12-05,CHIP ON LEAD FRAME FOR SMALL PACKAGE SPEED SENSOR,"A sensor package apparatus includes a lead frame substrate that supports one or more electrical components, which are connected to and located on the lead frame substrate. A plurality of wire bonds are also provided, which electrically connect the electrical components to the lead frame substrate, wherein the lead frame substrate is encapsulated by a thermoset plastic to protect the plurality of wire bonds and at least one electrical component, thereby providing a sensor package apparatus comprising the lead frame substrate, the electrical component(s), and the wire bonds, while eliminating a need for a Printed Circuit Board (PCB) or a ceramic substrate in place of the lead frame substrate as a part of the sensor package apparatus. A conductive epoxy can also be provided for maintaining a connection of the electrical component(s) to the lead frame substrate. The electrical components can constitute, for example, an IC chip and/or a sensing element (e.g., a magnetoresistive component) or sense die.",HONEYWELL INT INC,FRAZEE LAWRENCE E;;LAMB WAYNE A;;PATIN JOHN S;;SCHELONKA PETER A;;STOLFUS JOEL D,,https://lens.org/121-721-080-921-384,Patent Application,no,0,1,8,8,0,G01D11/245;;H01L23/49575;;H01L2224/48091;;H01L2224/49171;;H01L23/495;;G01P3/42;;G01D11/24;;H01L23/49575;;G01D11/245;;H01L2224/49171;;H01L2224/48091,H01L23/495;;G01D11/24;;G01P3/42,,0,0,,,,DISCONTINUED
104,WO,A1,WO 1992/005156 A1,002-483-963-248-503,1992-04-02,1992,US 9106494 W,1991-09-10,US 58195890 A,1990-09-13,PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS,"This invention relates to alkanoic acid compounds having pyridyl and arylthio or alkylthio substituents, or their oxygen analogs, which are useful as leukotriene antagonists.",SMITHKLINE BEECHAM CORP,FRAZEE JAMES SIMPSON;;GLEASON JOHN GERALD;;HALL RALPH FLOYD;;KINZIG CHARLES MICHAEL;;UZINSKAS IRENE NIJOLE,,https://lens.org/002-483-963-248-503,Patent Application,yes,1,12,10,10,0,A61P29/00;;A61P43/00;;C07D213/70;;C07D213/70;;C07D213/55,A61K31/44;;A61K31/4418;;A61P29/00;;A61P43/00;;C07D213/55;;C07D213/70,,0,0,,,,PENDING
105,PT,A,PT 98974 A,105-540-720-357-783,1992-08-31,1992,PT 9897491 A,1991-09-13,US 58195890 A,1990-09-13,PROCESSO DE PREPARACAO DE DERIVADOS DE ACIDOS PIRIDILTIO OU PIRIDILOXI-ALCANOICOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM,,SMITHKLINE BEECHAM CORP,GLEASON JOHN GERALD;;FRAZEE JAMES SIMPSON;;HALL RALPH FLOYD;;KINZIG CHARLES MICHAEL;;UZINSKAS IRENE NIJOLE,,https://lens.org/105-540-720-357-783,Patent Application,no,0,0,10,10,0,A61P29/00;;A61P43/00;;C07D213/70;;C07D213/70;;C07D213/55,A61K31/44;;A61K31/4418;;A61P29/00;;A61P43/00;;C07D213/55;;C07D213/70,,0,0,,,,DISCONTINUED
106,US,A,US 4594763 A,021-956-822-262-316,1986-06-17,1986,US 68514784 A,1984-12-21,US 68514784 A,1984-12-21,Method and apparatus for inserting a glass rod into a glass tube,"Insertion of a lightguide preform (12) into a tube (14) without contacting the sides thereof is accomplished by first roughly aligning the rod in spaced axial alignment with the tube. Thereafter, the offset of the rod from the axis of the tube is measured and the amount of lateral movement of the rod from the axis is determined. Then the rod is moved laterally in accordance with the determined amount of movement to precisely align the rod with the tube. Once alignment has been achieved, the rod is inserted in the tube and the tube is collapsed thereabout. An apparatus (10) for practicing this method is disclosed.",AT & T TECHNOLOGIES INC,FRAZEE JR RALPH E;;NIS JOHN R;;SANCHEZ JOSEPH;;SPAINHOUR CARROLL D;;STAWICKI ROBERT P,AT & T TECHNOLOGIES INC (1984-12-14);;FITEL USA CORPORATION (2001-11-16);;LUCENT TECHNOLOGIES INC (1996-03-29),https://lens.org/021-956-822-262-316,Granted Patent,yes,6,10,1,1,0,B23P19/10;;C03B37/01211;;Y02P40/57;;Y10T29/5303;;Y10T29/53009;;Y10T29/5303;;Y10T29/53009;;B23P19/10;;C03B37/01211;;Y02P40/57,B23P19/00;;C03B37/012,29/407;;29/702;;29/707;;65/29,0,0,,,,EXPIRED
107,US,S,US D0882436 S,093-453-904-812-024,2020-04-28,2020,US 201829673132 F,2018-12-12,US 201829673132 F,2018-12-12,Gas meter,,SENSUS SPECTRUM LLC,FRAZEE ERIC;;LONG KEVIN;;SOKOL BENJAMIN JOHN;;BRAZEAU MICHAEL DAVID;;HEALY DAVID;;MEANWELL HILARY JANE;;PATERSON CHARLIE,SENSUS SPECTRUM LLC (2018-11-06),https://lens.org/093-453-904-812-024,Design Right,no,4,5,1,1,0,,,1004;;D10/99,0,0,,,,ACTIVE
108,DE,B2,DE 2311114 B2,034-509-456-832-098,1981-05-27,1981,DE 2311114 A,1973-03-06,US 23646072 A,1972-04-26,DE 2311114 B2,,"W.R. GRACE & CO., 10036 NEW YORK, N.Y., US","FRAZEE, JOHN ROBERT, GAMBRILLS, MD., US;;MARTIN, BRIAN READ, CATONSVILLE, MD., US;;BRUNDRETT, CHARLES PHILIPP, BALTIMORE, MD., US",,https://lens.org/034-509-456-832-098,Patent Application,no,0,3,8,8,0,B01J23/868;;B01J23/868,B01J23/86,,0,0,,,,EXPIRED
109,DE,C3,DE 2311114 C3,187-305-364-906-604,1982-05-06,1982,DE 2311114 A,1973-03-06,US 23646072 A,1972-04-26,DE 2311114 C3,,"W.R. GRACE & CO., 10036 NEW YORK, N.Y., US","FRAZEE, JOHN ROBERT, GAMBRILLS, MD., US;;MARTIN, BRIAN READ, CATONSVILLE, MD., US;;BRUNDRETT, CHARLES PHILIPP, BALTIMORE, MD., US",,https://lens.org/187-305-364-906-604,Granted Patent,no,0,0,8,8,0,B01J23/868;;B01J23/868,B01J23/86,,0,0,,,,EXPIRED
110,WO,A3,WO 2008/008674 A3,129-888-160-606-531,2008-04-24,2008,US 2007/0072773 W,2007-07-03,US 48348106 A,2006-07-10,ENCODED LINEAR POSITION SENSOR,"Multiple magnetic sensing transducers can detect the position of a target. For example, a linear array of transducers can detect a target's linear position. A master and slave arrangement can reduce the cost and size of a system containing multiple magnetic sensing transducers. The master contains circuitry for voltage regulation and processing logic as well as a magnetic sensing transducer. The slaves contain a magnetic sensing transducer and little else. As such, the slave units are small and inexpensive. The slaves obtain power from the master, produce detection signals, and pass the detection signals to the master. The master interprets the detection signals along with an internal detection produced by the master's internal magnetic sensing transducer to produce a position signal.",HONEYWELL INT INC;;JOHNSON STEWART D;;ALFORS EUGENE D;;FRAZEE LAWRENCE E;;MURDOCK JOSEPH K;;CHILCOTE JASON M;;PATIN JOHN S,JOHNSON STEWART D;;ALFORS EUGENE D;;FRAZEE LAWRENCE E;;MURDOCK JOSEPH K;;CHILCOTE JASON M;;PATIN JOHN S,,https://lens.org/129-888-160-606-531,Search Report,yes,3,0,3,3,0,G01D5/145;;G01D5/147;;G01D21/00;;G01D5/145;;G01D5/147,G01D5/14,,0,0,,,,PENDING
111,WO,A2,WO 2008/008674 A2,004-182-108-559-822,2008-01-17,2008,US 2007/0072773 W,2007-07-03,US 48348106 A,2006-07-10,ENCODED LINEAR POSITION SENSOR,"Multiple magnetic sensing transducers can detect the position of a target. For example, a linear array of transducers can detect a target's linear position. A master and slave arrangement can reduce the cost and size of a system containing multiple magnetic sensing transducers. The master contains circuitry for voltage regulation and processing logic as well as a magnetic sensing transducer. The slaves contain a magnetic sensing transducer and little else. As such, the slave units are small and inexpensive. The slaves obtain power from the master, produce detection signals, and pass the detection signals to the master. The master interprets the detection signals along with an internal detection produced by the master's internal magnetic sensing transducer to produce a position signal.",HONEYWELL INT INC;;JOHNSON STEWART D;;ALFORS EUGENE D;;FRAZEE LAWRENCE E;;MURDOCK JOSEPH K;;CHILCOTE JASON M;;PATIN JOHN S,JOHNSON STEWART D;;ALFORS EUGENE D;;FRAZEE LAWRENCE E;;MURDOCK JOSEPH K;;CHILCOTE JASON M;;PATIN JOHN S,,https://lens.org/004-182-108-559-822,Patent Application,yes,0,2,3,3,0,G01D5/145;;G01D5/147;;G01D21/00;;G01D5/145;;G01D5/147,,,0,0,,,,PENDING
112,EP,B1,EP 2342160 B1,027-657-445-259-020,2012-12-26,2012,EP 09792696 A,2009-09-18,US 2009/0057436 W;;US 23615608 A,2008-09-23,INERTIAL SENSOR WITH DUAL CAVITY PACKAGE AND METHOD OF FABRICATION,,CUSTOM SENSORS & TECHNOLOGIES INC,BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,"CUSTOM SENSORS & TECHNOLOGIES, INC. (2012-12-19);;SYSTON DONNER INERTIAL, INC., US (2018-03-28);;SYSTRON DONNER INERTIAL, INC. (N.D.GES.D. STAA, US (2018-05-29)",https://lens.org/027-657-445-259-020,Granted Patent,yes,3,0,8,8,0,B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023,B81C1/00;;B81B7/00;;G01C19/5628;;G01C19/5783;;G01P1/02;;G01P15/09;;H01L23/057,,0,0,,,,ACTIVE
113,US,B2,US 8080925 B2,001-399-536-740-327,2011-12-20,2011,US 23615608 A,2008-09-23,US 23615608 A,2008-09-23,Inertial sensor with dual cavity package and method of fabrication,"Inertial sensor having a body with first and second cavities on opposite sides thereof, a sensing element in the first cavity, electronic circuitry in the second cavity, electrical conductors interconnecting the sensing element and the circuitry, and leads connected electrically to the circuitry and extending from the body for mounting the sensor and making connections with the circuitry.",BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR;;CUSTOM SENSORS & TECHNOLOGIES,BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,SYSTRON DONNER INERTIAL INC (2015-11-24);;CUSTOM SENSORS & TECHNOLOGIES INC (2008-09-22);;EMCOR CORPORATION (2022-01-19),https://lens.org/001-399-536-740-327,Granted Patent,yes,9,8,8,8,0,B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023,H01L41/08,310/370;;310/329;;310/348;;310/344,0,0,,,,ACTIVE
114,US,A1,US 2011/0010924 A1,022-038-955-357-734,2011-01-20,2011,US 88887010 A,2010-09-23,US 88887010 A;;US 23615608 A,2008-09-23,Inertial sensor with dual cavity package and method of fabrication,"Inertial sensor having a body with first and second cavities on opposite sides thereof, a sensing element in the first cavity, electronic circuitry in the second cavity, electrical conductors interconnecting the sensing element and the circuitry, and leads connected electrically to the circuitry and extending from the body for mounting the sensor and making connections with the circuitry.",CUSTOM SENSORS & TECHNOLOGIES INC,BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,SYSTRON DONNER INERTIAL INC (2015-11-24);;CUSTOM SENSORS & TECHNOLOGIES INC (2008-09-22);;EMCOR CORPORATION (2022-01-19),https://lens.org/022-038-955-357-734,Patent Application,yes,7,11,8,8,0,B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023,H05K13/00,29/592.1,0,0,,,,ACTIVE
115,US,A1,US 2010/0072862 A1,047-374-909-503-577,2010-03-25,2010,US 23615608 A,2008-09-23,US 23615608 A,2008-09-23,Inertial sensor with dual cavity package and method of fabrication,"Inertial sensor having a body with first and second cavities on opposite sides thereof, a sensing element in the first cavity, electronic circuitry in the second cavity, electrical conductors interconnecting the sensing element and the circuitry, and leads connected electrically to the circuitry and extending from the body for mounting the sensor and making connections with the circuitry.",CUSTOM SENSORS & TECHNOLOGIES,BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,SYSTRON DONNER INERTIAL INC (2015-11-24);;CUSTOM SENSORS & TECHNOLOGIES INC (2008-09-22);;EMCOR CORPORATION (2022-01-19),https://lens.org/047-374-909-503-577,Patent Application,yes,8,18,8,8,0,B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023,H01L41/08;;H01L41/22,310/370;;29/25.35,0,0,,,,ACTIVE
116,US,B2,US 8881370 B2,015-737-115-593-16X,2014-11-11,2014,US 88887010 A,2010-09-23,US 88887010 A;;US 23615608 A,2008-09-23,Method of fabricating an inertial sensor,"Inertial sensor having a body with first and second cavities on opposite sides thereof, a sensing element in the first cavity, electronic circuitry in the second cavity, electrical conductors interconnecting the sensing element and the circuitry, and leads connected electrically to the circuitry and extending from the body for mounting the sensor and making connections with the circuitry.",BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR;;CUSTOM SENSORS & TECHNOLOGIES,BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,SYSTRON DONNER INERTIAL INC (2015-11-24);;CUSTOM SENSORS & TECHNOLOGIES INC (2008-09-22);;EMCOR CORPORATION (2022-01-19),https://lens.org/015-737-115-593-16X,Granted Patent,yes,8,3,8,8,0,B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023,B81B7/00;;G01R31/28;;B81C1/00;;G01C19/5628;;G01C19/5783;;G01P1/02;;H01L23/057,29/593;;29/594;;29/595;;29/609.1;;310/321;;310/328;;310/330;;310/331;;310/332;;333/150;;333/187;;333/193;;333/195;;333/196,0,0,,,,ACTIVE
117,WO,A2,WO 2010/039453 A2,145-671-461-467-021,2010-04-08,2010,US 2009/0057436 W,2009-09-18,US 23615608 A,2008-09-23,INERTIAL SENSOR WITH DUAL CAVITY PACKAGE AND METHOD OF FABRICATION,"lnertial sensor having a body with first and second cavities on opposite sides thereof, a sensing element in the first cavity, electronic circuitry in the second cavity, electrical conductors interconnecting the sensing element and the circuitry, and leads connected electrically to the circuitry and extending from the body for mounting the sensor and making connections with the circuitry.",CUSTOM SENSORS & TECHNOLOGIES;;BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,,https://lens.org/145-671-461-467-021,Patent Application,yes,1,0,8,8,0,B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023,B81C1/00,,0,0,,,,PENDING
118,EP,A2,EP 2342160 A2,141-308-871-516-402,2011-07-13,2011,EP 09792696 A,2009-09-18,US 2009/0057436 W;;US 23615608 A,2008-09-23,INERTIAL SENSOR WITH DUAL CAVITY PACKAGE AND METHOD OF FABRICATION,,CUSTOM SENSORS & TECHNOLOGIES INC,BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,"CUSTOM SENSORS & TECHNOLOGIES, INC. (2012-12-19);;SYSTON DONNER INERTIAL, INC., US (2018-03-28);;SYSTRON DONNER INERTIAL, INC. (N.D.GES.D. STAA, US (2018-05-29)",https://lens.org/141-308-871-516-402,Patent Application,yes,0,0,8,8,0,B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023,B81C1/00;;B81B7/00;;G01C19/5628;;G01C19/5783;;G01P1/02;;G01P15/09;;H01L23/057,,0,0,,,,ACTIVE
119,WO,A3,WO 2010/039453 A3,011-368-779-995-421,2011-01-27,2011,US 2009/0057436 W,2009-09-18,US 23615608 A,2008-09-23,INERTIAL SENSOR WITH DUAL CAVITY PACKAGE AND METHOD OF FABRICATION,"lnertial sensor having a body with first and second cavities on opposite sides thereof, a sensing element in the first cavity, electronic circuitry in the second cavity, electrical conductors interconnecting the sensing element and the circuitry, and leads connected electrically to the circuitry and extending from the body for mounting the sensor and making connections with the circuitry.",CUSTOM SENSORS & TECHNOLOGIES INC;;BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,BERGER WILLIAM PAUL;;COLLINS MARK ANDREW;;FRAZEE MICHAEL THOMAS;;SMITH THAD W MARC;;ANDERSON ROBERT ALBERT;;KNOWLES STUART JOHN;;DRAGOTTI VICTOR,,https://lens.org/011-368-779-995-421,Search Report,yes,3,0,8,8,0,B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;Y10T29/42;;Y10T29/49004;;Y10T29/49007;;Y10T29/4908;;Y10T29/49005;;Y10T29/49002;;B81B7/0058;;B81B2201/0235;;B81B2207/012;;B81C1/0023;;G01C19/5628;;G01C19/5783;;H01L23/057;;H01L2924/1433;;H01L2224/49171;;G01P1/023,B81C1/00;;B81B7/00;;H01L23/057,,0,0,,,,PENDING
120,US,B2,US 7365085 B2,013-953-181-300-461,2008-04-29,2008,US 50889404 A,2004-09-22,US 50889404 A;;US 36842502 P;;US 0309450 W,2002-03-27,Compounds and methods,"Disclosed is a compound having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.",SMITHKLINE BEECHAM CORP,BHAT AJITA;;MCATEE JOHN JEFFREY;;THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH;;NEEB MICHAEL J;;STAVENGER ROBERT A,GLAXOSMITHKLINE LLC (2003-03-20),https://lens.org/013-953-181-300-461,Granted Patent,yes,29,22,10,10,2,C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07C311/29;;C07C217/36;;C07C311/09;;C07D213/38;;C07D317/58;;C07D317/68;;C07D319/18;;C07D307/66;;C07C217/20;;C07D257/04;;C07C229/34;;C07C291/02;;C07C275/34;;C07D249/08;;C07C323/32;;C07D233/64;;C07D295/096;;C07D295/125;;C07C219/22;;C07D239/42;;C07C311/08;;C07D295/185;;C07C309/73;;C07D211/34;;C07C233/25;;C07C311/21;;C07D213/74;;C07C271/28;;C07D211/60;;C07D333/20;;C07C217/22;;C07C217/18;;C07D213/64;;C07D231/14;;C07D307/68;;C07C2601/02;;C07C2601/04;;C07C2601/08,A01N43/40;;A01N43/08;;A01N43/64;;A61K31/41;;A61K31/44;;A61P9/00;;C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C239/08;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C311/45;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/54;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07D401/02,514/357;;514/381;;514/383;;514/471;;514/538;;514/539;;514/568;;514/651;;546/300;;548/252;;560/27;;560/29;;562/431;;564/442;;564/443,32,23,001-516-175-552-397;;006-339-151-174-691;;111-477-648-971-073;;089-192-774-638-365;;115-402-406-326-441;;104-407-312-389-939;;073-481-283-712-161;;036-103-726-103-892;;026-670-697-347-713;;103-025-353-088-059;;047-828-578-591-421;;104-476-103-014-208;;025-426-021-859-11X;;004-087-461-018-482;;141-975-061-008-886;;034-139-850-554-14X;;055-840-563-684-053;;021-128-513-067-433;;039-812-740-681-825;;031-606-585-295-810;;034-880-953-200-864;;089-192-774-638-365;;005-406-492-995-595,10.1016/s0169-409x(01)00097-7;;11325474;;10.1021/ar00046a004;;10.1016/s0040-4039(97)00650-3;;11985463;;10.1021/jm0255116;;15941783;;10.1152/ajpendo.00165.2005;;16024916;;10.1194/jlr.m500116-jlr200;;16107141;;10.1021/jm050532w;;15790955;;10.1161/01.res.0000163630.86796.17;;15292374;;10.1194/jlr.m400257-jlr200;;10.1194/jlr.m300450-jlr200;;15145986;;15191540;;10.1111/j.0022-202x.2004.22707.x;;10.1074/jbc.m304842200;;12819202;;10.1016/s1093-3263(03)00159-1;;12932788;;10.1046/j.1523-1747.2003.12033.x;;12542530;;pmc124297;;12032330;;10.1073/pnas.112059299;;16354191;;10.1111/j.0022-202x.2005.23964.x;;16365197;;10.1161/circulationaha.105.560177;;15633131;;10.1053/j.gastro.2004.10.006;;12697904;;10.1073/pnas.0830671100;;pmc154360;;10.1074/jbc.m213071200;;12531895;;12612088;;pmc149472;;10.1128/mcb.23.6.2182-2191.2003;;11985463;;10.1021/jm0255116;;10.1111/j.1742-4658.2005.04599.x;;15752369,"Vippagunta et al, ""Crystalline Solids"" Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).;;Gavezzotti, ""Are Crystal Structures Predictable?"" Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).;;U.S. Appl. 60/499,659, filed Sep. 3, 2003, Hoang et al.;;U.S. Appl. 60/500,295, filed Sep. 4, 2003, Hoang et al.;;U.S. Appl. 60/499,779, filed Sep. 3, 2003, Kallander et al.;;U.S. Appl. 60/500,296, filed Sep. 4, 2003, Kallander et al.;;U.S. Appl. 60/499,762, filed Sep. 3, 2004, Hoang et al.;;Siegel et al., ""Rapid Purification of Small Molecule Libraries by Ion Exchange Chromatography"". Tetrahedron Lett., 38(19): 3357-3360 (1997).;;Collins et al., ""Identification of a Nonsteroidal Liver X Receptor Agonist Through Parallel Array Synthesis of Tertiary Amines"", J. Med. Chem., 45: 1963-1966 (2002).;;Grefhorst et al. Am. J. Physiol. Endocrinol. Metab., 289: E829-E838 (2005).;;Groot et al. J. Lipid Res., 46: 2182-2191 (2005).;;Jaye et al. J. Med. Chem., 48: 5419-5422 (2005).;;Ogawa et al. Circ. Res., 96: e59-e67 (2005).;;Quinet et al. J. Lipid Res., 45: 1929-1942 (2004).;;Miao et al. J. Lipid Res., 45: 1410-1417 (2004).;;Schmuth et al. J. Invest. Dermatol. 123: 41-48 (2004).;;Farnegardh et al. J. Biol. Chem., 278(40): 38821-38828 (2003).;;Wang et al. J. Molec. Graphics and Modelling, 22: 173-181 (2003).;;Fowler et al. J. Invest. Dermatol., 120: 246-255 (2003).;;Joseph et al. PNAS USA, 99(11): 7604-7609 (2002).;;Fluhr et al. J. Invest. Dermatol., 125: 1206-1214 (2005).;;Naik et al. Circulation, 113: 90-97 (2006).;;Kruit et al. Gastroenterology, 128: 147-156 (2005).;;Laffitte et al. PNAS USA, 100(9): 5419-5424 (2003).;;Castrillo et al. J. Biol. Chem., 278(12): 10443-10449 (2003).;;Laffitte et al. Mol. & Cell. Biol., 23(6): 2182-2191 (2003).;;Collins et al. J. Med. Chem., 45: 1963-1966 (2002).;;Terasaka et al. FEBS Journal, 272: 1546-1556 (2005).;;Collins et al. Abstracts of Papers, 230<SUP>th </SUP>ACS National Meeting, Washington, DC. Aug. 28-Sep. 1, 2005. MEDI-237. Publisher: American Chemical Society, Washington, DC.;;Rao et al. Abstracts of Papers, 229<SUP>th </SUP>ACS National Meeting, San Diego, CA. Mar. 13-17, 2005. COMP-258. Publisher: American Chemical Society, Washington, DC.;;Jon L. Collins. Abstracts of Papers, 225<SUP>th </SUP>ACS National Meeting, New Orleans, LA. Mar. 23-27, 2003. MEDI-152. Publisher: American Chemical Society, Washington, DC.;;Collins et al. Abstracts of Papers, 223<SUP>rd </SUP>ACS National Meeting, Orlando, FL. Apr. 7-11, 2002. MEDI-123. Publisher: American Chemical Society, Washington, DC.",EXPIRED
121,WO,A2,WO 2003/082205 A2,072-494-169-102-155,2003-10-09,2003,US 0309450 W,2003-03-26,US 36842502 P,2002-03-27,COMPOUNDS AND METHODS,"Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.",SMITHKLINE BEECHAM CORP;;THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH P;;NEEB MICHAEL J;;BHAT AJITA;;MCATEE JOHN JEFFREY;;STAVENGER ROBERT A,THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH P;;NEEB MICHAEL J;;BHAT AJITA;;MCATEE JOHN JEFFREY;;STAVENGER ROBERT A,,https://lens.org/072-494-169-102-155,Patent Application,yes,0,0,10,10,0,C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07C311/29;;C07C217/36;;C07C311/09;;C07D213/38;;C07D317/58;;C07D317/68;;C07D319/18;;C07D307/66;;C07C217/20;;C07D257/04;;C07C229/34;;C07C291/02;;C07C275/34;;C07D249/08;;C07C323/32;;C07D233/64;;C07D295/096;;C07D295/125;;C07C219/22;;C07D239/42;;C07C311/08;;C07D295/185;;C07C309/73;;C07D211/34;;C07C233/25;;C07C311/21;;C07D213/74;;C07C271/28;;C07D211/60;;C07D333/20;;C07C217/22;;C07C217/18;;C07D213/64;;C07D231/14;;C07D307/68;;C07C2601/02;;C07C2601/04;;C07C2601/08,A61P9/00;;C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C239/08;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C311/45;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/54;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07D401/02,,0,0,,,,PENDING
122,JP,A,JP 2010043112 A,078-382-313-637-210,2010-02-25,2010,JP 2009235246 A,2009-10-09,US 36842502 P,2002-03-27,COMPOUND AND METHOD FOR USING THE SAME,"<P>PROBLEM TO BE SOLVED: To provide a compound useful for treating such diseases as inflammations, cardiovascular disorders and atherosclerosis as liver X receptor (LXR)-mediated diseases or symptoms. <P>SOLUTION: The compound is represented by formula (I) (wherein, X is bromo, carboxyl, hydroxyl or the like; R<SP>1</SP>to R<SP>9</SP>are each independently H, halo, 1-6C alkyl or the like; Z is CH or N; Y is -O- or the like; W<SP>1</SP>to W<SP>3</SP>are each H, methyl, phenyl or the like; Q is 2-chloro-3-(trifluoromethyl)phenyl or the like; p is 0-2; n is 3; m is 0 or 1; q is 1; and t is 0 or 1). <P>COPYRIGHT: (C)2010,JPO&INPIT",GLAXOSMITHKLINE LLC,THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH P;;NEEB MICHAEL J;;BHAT AJITA;;MCATEE JOHN JEFFREY;;STAVENGER ROBERT A,,https://lens.org/078-382-313-637-210,Patent Application,no,2,0,10,10,0,C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07C311/29;;C07C217/36;;C07C311/09;;C07D213/38;;C07D317/58;;C07D317/68;;C07D319/18;;C07D307/66;;C07C217/20;;C07D257/04;;C07C229/34;;C07C291/02;;C07C275/34;;C07D249/08;;C07C323/32;;C07D233/64;;C07D295/096;;C07D295/125;;C07C219/22;;C07D239/42;;C07C311/08;;C07D295/185;;C07C309/73;;C07D211/34;;C07C233/25;;C07C311/21;;C07D213/74;;C07C271/28;;C07D211/60;;C07D333/20;;C07C217/22;;C07C217/18;;C07D213/64;;C07D231/14;;C07D307/68;;C07C2601/02;;C07C2601/04;;C07C2601/08,C07C217/18;;A61K31/138;;A61K31/165;;A61K31/167;;A61K31/17;;A61K31/18;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/216;;A61K31/235;;A61K31/27;;A61K31/341;;A61K31/357;;A61K31/36;;A61K31/381;;A61K31/40;;A61K31/41;;A61K31/415;;A61K31/417;;A61K31/4196;;A61K31/44;;A61K31/451;;A61K31/4525;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/5375;;A61K31/5377;;A61K31/54;;A61P3/06;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P43/00;;C07C217/20;;C07C217/22;;C07C217/36;;C07C217/48;;C07C217/84;;C07C219/22;;C07C229/14;;C07C229/18;;C07C229/34;;C07C233/25;;C07C233/60;;C07C235/08;;C07C239/08;;C07C255/54;;C07C271/28;;C07C275/34;;C07C291/02;;C07C291/04;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C311/45;;C07C323/32;;C07D207/16;;C07D207/333;;C07D207/335;;C07D211/14;;C07D211/22;;C07D211/34;;C07D211/60;;C07D211/62;;C07D213/36;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/54;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/08;;C07D295/096;;C07D295/12;;C07D295/125;;C07D295/14;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07D401/02,,0,0,,,,PENDING
123,EP,A4,EP 1575495 A4,017-984-497-454-51X,2009-12-02,2009,EP 03745638 A,2003-03-26,US 0309450 W;;US 36842502 P,2002-03-27,COMPOUNDS AND METHODS,,SMITHKLINE BEECHAM CORP,THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH P;;NEEB MICHAEL J;;BHAT AJITA;;MCATEE JOHN JEFFREY;;STAVENGER ROBERT A,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/017-984-497-454-51X,Search Report,no,6,0,10,10,0,C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07C311/29;;C07C217/36;;C07C311/09;;C07D213/38;;C07D317/58;;C07D317/68;;C07D319/18;;C07D307/66;;C07C217/20;;C07D257/04;;C07C229/34;;C07C291/02;;C07C275/34;;C07D249/08;;C07C323/32;;C07D233/64;;C07D295/096;;C07D295/125;;C07C219/22;;C07D239/42;;C07C311/08;;C07D295/185;;C07C309/73;;C07D211/34;;C07C233/25;;C07C311/21;;C07D213/74;;C07C271/28;;C07D211/60;;C07D333/20;;C07C217/22;;C07C217/18;;C07D213/64;;C07D231/14;;C07D307/68;;C07C2601/02;;C07C2601/04;;C07C2601/08,A61P9/00;;C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C239/08;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C311/45;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/54;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07D401/02,,0,0,,,,DISCONTINUED
124,WO,A3,WO 2003/082205 A3,061-376-103-330-511,2009-04-16,2009,US 0309450 W,2003-03-26,US 36842502 P,2002-03-27,COMPOUNDS AND METHODS,"Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.",SMITHKLINE BEECHAM CORP;;THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH P;;NEEB MICHAEL J;;BHAT AJITA;;MCATEE JOHN JEFFREY;;STAVENGER ROBERT A,THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH P;;NEEB MICHAEL J;;BHAT AJITA;;MCATEE JOHN JEFFREY;;STAVENGER ROBERT A,,https://lens.org/061-376-103-330-511,Search Report,yes,0,0,10,10,0,C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07C311/29;;C07C217/36;;C07C311/09;;C07D213/38;;C07D317/58;;C07D317/68;;C07D319/18;;C07D307/66;;C07C217/20;;C07D257/04;;C07C229/34;;C07C291/02;;C07C275/34;;C07D249/08;;C07C323/32;;C07D233/64;;C07D295/096;;C07D295/125;;C07C219/22;;C07D239/42;;C07C311/08;;C07D295/185;;C07C309/73;;C07D211/34;;C07C233/25;;C07C311/21;;C07D213/74;;C07C271/28;;C07D211/60;;C07D333/20;;C07C217/22;;C07C217/18;;C07D213/64;;C07D231/14;;C07D307/68;;C07C2601/02;;C07C2601/04;;C07C2601/08,C07D211/72;;A61P9/00;;C07C211/00;;C07C213/00;;C07C215/00;;C07C217/00;;C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/00;;C07C229/34;;C07C233/25;;C07C239/08;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C311/45;;C07C323/32;;C07D211/34;;C07D211/60;;C07D211/84;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/54;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07D401/02;;C07D413/00;;C09B11/02,,2,2,111-477-648-971-073;;089-192-774-638-365,10.1016/s0040-4039(97)00650-3;;11985463;;10.1021/jm0255116,"SIEGEL ET AL.: ""Rapid Purification of Small Molecule Libraries by Ion Excahange Chromatography."", TETRAHEDRON LETTERS, vol. 38, no. 19, 1997, pages 3357 - 3360, XP004061425;;COLLINS ET AL.: ""Identification of a Nonsteroidal Liver X Receptor Agonist Through Parallel Array Synthesis of Tertiary Amines."", J. MED. CHEM., vol. 45, 17 April 2002 (2002-04-17), pages 1963 - 1966, XP002225147",PENDING
125,EP,A2,EP 1575495 A2,197-460-776-397-191,2005-09-21,2005,EP 03745638 A,2003-03-26,US 0309450 W;;US 36842502 P,2002-03-27,COMPOUNDS AND METHODS,,SMITHKLINE BEECHAM CORP,THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH P;;NEEB MICHAEL J;;BHAT AJITA;;MCATEE JOHN JEFFREY;;STAVENGER ROBERT A,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/197-460-776-397-191,Patent Application,yes,0,0,10,10,2,C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07C311/29;;C07C217/36;;C07C311/09;;C07D213/38;;C07D317/58;;C07D317/68;;C07D319/18;;C07D307/66;;C07C217/20;;C07D257/04;;C07C229/34;;C07C291/02;;C07C275/34;;C07D249/08;;C07C323/32;;C07D233/64;;C07D295/096;;C07D295/125;;C07C219/22;;C07D239/42;;C07C311/08;;C07D295/185;;C07C309/73;;C07D211/34;;C07C233/25;;C07C311/21;;C07D213/74;;C07C271/28;;C07D211/60;;C07D333/20;;C07C217/22;;C07C217/18;;C07D213/64;;C07D231/14;;C07D307/68;;C07C2601/02;;C07C2601/04;;C07C2601/08,A61P9/00;;C07D211/72;;C07C211/00;;C07C213/00;;C07C215/00;;C07C217/00;;C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/00;;C07C229/34;;C07C233/25;;C07C239/08;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C311/45;;C07C323/32;;C07D211/34;;C07D211/60;;C07D211/84;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/54;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07D401/02;;C07D413/00;;C09B11/02,,0,0,,,,DISCONTINUED
126,AU,A1,AU 2003/226094 A1,053-978-474-941-504,2003-10-13,2003,AU 2003/226094 A,2003-03-26,US 36842502 P;;US 0309450 W,2002-03-27,COMPOUNDS AND METHODS,,SMITHKLINE BEECHAM CORP,THOMPSON SCOTT K;;FRAZEE JAMES S;;KALLANDER LARA S;;MA CHUN;;MARINO JOSEPH P;;NEEB MICHAEL J;;BHAT AJITA;;MCATEE JOHN JEFFREY;;STAVENGER ROBERT A,,https://lens.org/053-978-474-941-504,Patent Application,no,0,4,10,10,0,C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07C311/29;;C07C217/36;;C07C311/09;;C07D213/38;;C07D317/58;;C07D317/68;;C07D319/18;;C07D307/66;;C07C217/20;;C07D257/04;;C07C229/34;;C07C291/02;;C07C275/34;;C07D249/08;;C07C323/32;;C07D233/64;;C07D295/096;;C07D295/125;;C07C219/22;;C07D239/42;;C07C311/08;;C07D295/185;;C07C309/73;;C07D211/34;;C07C233/25;;C07C311/21;;C07D213/74;;C07C271/28;;C07D211/60;;C07D333/20;;C07C217/22;;C07C217/18;;C07D213/64;;C07D231/14;;C07D307/68;;C07C2601/02;;C07C2601/04;;C07C2601/08,A61P9/00;;C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C239/08;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C311/45;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/54;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07D401/02,,0,0,,,,DISCONTINUED
127,AU,A8,AU 2003/226094 A8,081-627-468-906-711,2009-05-14,2009,AU 2003/226094 A,2003-03-26,US 36842502 P;;US 0309450 W,2002-03-27,Compounds and methods,,SMITHKLINE BEECHAM CORP,KALLANDER LARA S;;STAVENGER ROBERT A;;MARINO JOSEPH P;;BHAT AJITA;;MCATEE JOHN JEFFREY;;THOMPSON SCOTT K;;MA CHUN;;FRAZEE JAMES S;;NEEB MICHAEL J,,https://lens.org/081-627-468-906-711,Patent Application,no,0,0,10,10,0,C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/34;;C07C233/25;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C323/32;;C07D211/34;;C07D211/60;;C07D213/38;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/64;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07C311/29;;C07C217/36;;C07C311/09;;C07D213/38;;C07D317/58;;C07D317/68;;C07D319/18;;C07D307/66;;C07C217/20;;C07D257/04;;C07C229/34;;C07C291/02;;C07C275/34;;C07D249/08;;C07C323/32;;C07D233/64;;C07D295/096;;C07D295/125;;C07C219/22;;C07D239/42;;C07C311/08;;C07D295/185;;C07C309/73;;C07D211/34;;C07C233/25;;C07C311/21;;C07D213/74;;C07C271/28;;C07D211/60;;C07D333/20;;C07C217/22;;C07C217/18;;C07D213/64;;C07D231/14;;C07D307/68;;C07C2601/02;;C07C2601/04;;C07C2601/08,C07D211/72;;A61P9/00;;C07C211/00;;C07C213/00;;C07C215/00;;C07C217/00;;C07C217/18;;C07C217/20;;C07C217/22;;C07C217/36;;C07C219/22;;C07C229/00;;C07C229/34;;C07C233/25;;C07C239/08;;C07C271/28;;C07C275/34;;C07C291/02;;C07C309/73;;C07C311/08;;C07C311/09;;C07C311/21;;C07C311/29;;C07C311/45;;C07C323/32;;C07D211/34;;C07D211/60;;C07D211/84;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/74;;C07D231/14;;C07D233/54;;C07D239/42;;C07D249/08;;C07D257/04;;C07D295/096;;C07D295/125;;C07D295/185;;C07D307/66;;C07D307/68;;C07D317/58;;C07D317/68;;C07D319/18;;C07D333/20;;C07D401/02;;C07D413/00;;C09B11/02,,0,0,,,,DISCONTINUED
